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ABSTRACT
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Under the Supervision of Associate Professor Dr. Yi-Qiang Cheng

Histone deacetylase (HDAC) inhibitors are becoming increasingly valuable
therapeutic agents in treatment of several types of malignancies. FK228 is a depsipeptde
anticancer compound produced by Chromobacterium violaceum no. 968 through a
nonribosomal peptide synthetase (NRPS)-polyketide synthase (PKS) hybrid assembly
line. In the present study, reconstitution of the biosynthetic pathway responsible for the
production of FK228 revealed cross-talk between modular PKS and fatty acid synthase.
This pathway contains two PKS modules on the DepBC enzymes that lack a functional
acyltransferase (AT) domain, and no apparent AT-encoding gene exists within the gene
cluster or its vicinity. We reported through heterologous expression of the FK228
biosynthetic pathway in E. coli cells, two essential genes, fabD1 and fabD2, both
encoding a putative malonyl CoA acyltransferase component of the fatty acid synthase
complex, are positively identified to be involved in FK228 biosynthesis. Either gene
product appears sufficient to complement the “AT-less” PKS modules on DepBC for
polyketide chain elongation. Concurrently a gene (sfp) encoding a putative Sfp-type
phosphopantetheinyltransferase was identified to be necessary for FK228 biosynthesis as
well. Importantly, engineered E. coli strains carrying variable genetic components
produced significant levels of FK228 under both aerobic and anaerobic cultivation
ii

conditions. Discovery of the trans complementation of modular PKSs by housekeeping
ATs reveals natural product biosynthesis diversity. Moreover, demonstration of anaerobic
production of FK228 by an engineered facultative bacterial strain validates our effort
toward engineering of novel tumor-targeting bio-agents. The second part of the
dissertation focused on the engineering of cell penetrating peptides (CPPs) with
anticancer activity. A fusion protein combining the transmembrane activity of a bacterial
CPP with a eukaryotic mitochondrial disrupting protein (MDP) was constructed to
become a new CPP-MDP protein with anticancer activity. A new E. coli BL21(DE3)based expression system that facilitates the secretion of CPP fusion proteins into the
growth media for rapid and efficient protein purification was also created. This protein
secretion system utilizes induced L-form bacterial spheroplasts to generate a yield of 32
mg/L of CPP-MDP directly from the media. Construction of an L-form based E. coli
BL21 (DE3) protein secretion system and a modular CPP expression system allows
future rapid CPP-fusion protein production with new fusion protein partners to develop
new CPP-based anticancer agents.
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CHAPTER 1

INTRODUCTION
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1.1 Targeting Cancer
Cancer continues to be a major public health problem and the development of
effective cancer treatments with no or few side effects remains one of the most difficult
scientific challenges in medicine. Cancer occurs in many tissue types (such as breast
cancer, skin cancer, or leukemia) and the effectiveness of conventional treatments
(surgical removal, radiotherapy and chemotherapy) varies (1). Consequently, there have
been intensive efforts to develop alternative cancer therapies including bone marrow
transplantation, immunotherapy, gene therapy, hormone therapy, and inhibition of
angiogenesis (formation of blood vessels) or specific protein targets (mostly kinases) in
key signaling pathways, with mixed success (2). Many current therapies using radiation,
platinum and nucleic acid analogs have activity against cancer cells but are also toxic to
normal tissue. Furthermore, many cancer cell lines have developed resistance to one or
all of these treatments, limiting their effectiveness (3). Current goals in the development
of new anticancer agents combine high activity toward cancer cells while limiting
toxicity to preserve healthy tissue. In order to overcome issues of toxicity and resistance,
research has focused on developing new therapies that target specific cellular pathways in
cancer cells such as apoptosis, cell cycle regulation, mitochondrial growth and repair,
endoplasmic protein folding and transport and reactive oxygen species (ROS) repair.
The trademark of cancer cells is the development of pro-cancer genetic and
epigenetic changes that uncouple the regulatory controls of both cellular division and cell
death. These genetic mutational and transcriptional activities impart new survival
advantages over normal tissue. The aberrant cancer cells gain the ability to infinitely
divide and out-compete surrounding cells for nutrients. Furthermore, the new genetic
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influences lead to the rapid growth of tumors and the physiologic changes that preserve
the abnormal cells.

1.2 Epigenetics of Cancer
Traditional cancer research focuses on genetic regulation and the respective
mutations that lead to the various cancer phenotypes. The field of epigenetics relates to
the inherited genetic expression patterns associated with environmental adaptation (4).
Both the genetic and epigenetic changes are important determinants of cancer
development and progression, and epigenetic changes may preclude mutational changes
leading to cancer. In comparison to inherited genetic changes, inherited epigenetic gene
transcription levels are environmentally linked adaptations and are reversible
chromosomal structure changes that exert significant control on chromosomal activation
and gene regulation. Epigenetic chromosomal changes can favor genetic mutation, and
enhance gene mutation effects by deactivating a chromosomal region related to the
activation of oncogenes and tumor suppressor genes (5). Current epigenetic research
therefore focuses on determining the effect of gene mutations or DNA sequence changes
from epigenetic changes with regard to onset and progression of cancer. As with genetic
mutations, epigenetic changes may alter more than one pathway leading to the
development of a pro-cancerous state or cancer. In many cases, frequent epigenetic
changes may create a cancer susceptible cell which is prone to develop genetic mutation
leading to a cancerous state (4).
The reversible chromosomal modifications are capable of converting a “malignant
state” of a cell to a “normal state” either through intrinsic factors or with extrinsic factors
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targeting epigenetic chromosomal modifications. Two major epigenetic changes in the
cell targeted to return a malignant cell to a normal gene expression state are DNA
methylation and modifications of the histone tails including acetylation (4, 6) have been
elucidated. It is hypothesized that both DNA methylation and histone acetylation result in
similar changes in the control of regional chromosomal activation. DNA methylation is
controlled by DNA methyl transferases (DMT), while histone tail modifications are either
methylated or acetylated. The methyl regulation of the histone tails are coordinated by
reversible histone methyl transferases (HMT) that adds or removes methyl groups from
the N terminal histone tails. Alternatively, the histone acetyl transferases (HAT) add
acetyl groups onto lysine residues on histone tails and histone deacetylases (HDAC)
catalyze removal of acetyl groups from lysine residues on histone tails.
The major epigenetic changes associated with cancer are related to the regulatory
activities of HAT and HDAC which usually determine chromosomal activity states.
DNA exists in one of two structural states; euchromatin (open for transcription) or
heterochromatin (closed for transcription). Increased euchromatin based transcription
activity is related to HAT activity by increasing the acetylation of histone tail lysine
residues, which decreases the affinity of DNA to histones, resulting in an open
transcription state. In contrast, HDAC activity removes acetyl groups from histone tails,
increasing the affinity of DNA to histones causing an increase in chromatin compaction
preventing transcription (4, 6) (Figure 1). The reversion of deactivated chromosomal
regions is the focus of epigenetic therapy aiming to reactivate transcription of tumor
suppressor genes and other genes that are related to a normal cell gene expression state
(7). Two common epigenetic therapies currently on the market involve inhibitors of
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DMTs and HDACs. The correlation between histone tail lysine acetylation and chromatin
remodeling producing an open transcription state was demonstrated to be an effective
epigenetic anticancer therapy where HDAC inhibition resulted in an increased open
chromatin structure (6). The effectiveness of HDAC inhibition has led to the continued
search and development of new compounds targeting the specific HDACs to elucidate the
chromosomal remodeling pathways.

Figure 1. The methylation and acetylation epigenetic modifications of DNA and
chromosomes regulate the gene transcriptional processes. Normally, the conversion of
genetic information encoded in the DNA into gene products via transcription, requires the
DNA to be in an "open" state where histone proteins (light blue) are modified by the
addition of acetyl groups (green). Acetylation of the histones tails results in a relaxed
chromatin configuration allowing the transcriptional machinery access to the DNA.
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DNA methyltransferases (DNMTs), can add methyl groups (red) to the DNA at specific
sequences of DNA causing the recruitment of methyl binding domain (MBD) protein
complexes that includes repressor proteins, such as histone deacetylases (HDAC). The
HDACs remove acetyl groups from histone proteins resulting in condensed chromatin
that blocks the transcriptional machinery. Therefore, both DNMT and HDAC cause a
reduction in gene transcription and may deactivate key tumor suppressor genes. New
therapies targeting DNMTs and HDACs that inhibit these enzymes can return the
chromatin to a relaxed state, allowing gene transcription. Adapted from Moonat and
Pandey, 2012 (8).

1.3 Human HDAC Classes and Function
The discovery of chromosomal inactivation associated with tumor suppressor
gene silencing has identified HDACs as a potential target in epigenetic cancer therapy
(9). The human HDAC superfamily is divided into classes I, II, III and IV based on
structure, phylogeny and biological activity (10). Classes I, II and IV are termed
“classical HDACs” containing zinc as a cofactor in the catalytic pocket. The classical
HDACs reaction cleaves the amide bond between ε-amino group on lysine residues and
the terminal acetyl group in the N-terminal tail. Class III HDACs are also called the
sirtuins and contain nicotine adenine di-nucleotide (NAD)-dependent enzymes, including
the silent information regulator (Sir)-2 family (11). Currently, only the classical HDAC
family has been targeted for epigenetic therapy and many inhibitors of this family have
progressed through clinical trials and on to the market as therapeutic agents (12, 13).
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Currently, the human genome contains 18 HDACs belonging to the four superfamily
classes. The Class I HDACs contains HDAC1, HDAC2, HDAC3 and HDAC8 and are
localized only in the nucleus. While, Class II consists of HDAC4, HDAC5, HDAC6,
HDAC7, HDAC9 and HDAC10 and are found in the cytoplasm but can also migrate to
the nucleus. Class IV consists of the hybrid HDAC11, that shares similarity with both
class I and class II HDACs. The remaining seven HDAC members are zinc-independent
and NAD-dependent enzymes belonging to Class III HDACs.
Structural examination of Class I HDACs identified the catalytic mechanism
associated with acetyl transferase activity and inhibition. The catalytic pocket responsible
for hydrolysis of acetyl-lysine amide bond contains a Zn2+ ion. The ion is bound to two
negatively charged aspartic acid residues and one histidine residue, leaving open two
coordination sites for acetyl-lysine interactions from histone tails (14). The crystal
structure of the HDAC8 catalytic pocket was shown to resemble a long tunnel largely
composed of hydrophobic residues. This hydrophobic tunnel was postulated to make
contact with the lysine residues from histone tails and guide the terminal acetyl group to
the catalytic core. Also, the amino acids surrounding the entrance to the catalytic pocket
of HDACs are responsible for surface recognition interactions critical to selectivity. The
structural information of the catalytic center and surrounding pocket provide important
information related to the design of HDAC inhibitors (14, 15).

1.4 Effects of HDAC Inhibition
HDAC inhibition has been connected with broad epigenetic changes with various
anticancer effects such as increase in genome wide gene expression, anti-angiogenesis,
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cell cycle arrest, cellular differentiation, apoptosis and tumor regression (Figure 2) (16,
4). The therapeutic action of HDACs inhibition leads to hyper-acetylation of histones
which reduces the affinity of DNA to histones because of the neutralized positive charge
on lysine residues. The euchromatin open structure is thought to increase the gene
expression of tumor suppressor genes which is one of the various mechanisms suggested
for anticancer effects stemming from HDAC inhibition (17). In particular, acetylation of
histones has been shown to direct chromatin assembly, DNA recombination and repair
(18). Also, inhibition of HDACs may affect both histone HDACs and non-histone
substrates leading to similar results (16). While there is considerable difference in the
mechanisms proposed for the anticancer effects, new evidence has shown HDAC
inhibition increases the expression of pro-apoptosis signals suppressed in cancer cells
(19). Also, anticancer chromosomal changes are dependent on which HDACs they
inhibit. HDAC inhibitors may be termed as pan-HDAC inhibitors which inhibit all
classical HDACs, or as isoform-selective inhibitors which inhibit only a certain class
(20). There is evidence suggesting that pan-HDAC inhibitors affect multiple cellular
pathways that are dependent on acetylation of histone tails and are not related to onset or
progression of cancer. Events resulting from nonspecific HDAC inhibition may be
circumvented with application of isoform-specific HDACi (17). This evidence suggests
isoform-specific HDAC inhibitors may provide critical insight into the regulation of
epigenetic chromosomal changes and identifies the need for new HDAC inhibitors that
limit broad changes in expression patterns.
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Figure 2. Pathway specificity and expression levels of class I and Class II HDACs lead
to cancer phenotypes. Decreased expression (red lines) of specific HDACs result in
apoptosis, cell cycle arrest and growth inhibition. In contrast, overexpression (green
arrows) of specific HDACs increases proliferation, resistance to chemotherapy, cancer
cell migration and angiogenesis. FK228 has strong inhibitory action on class I HDAC 1
and HDAC 2, reversing the HDAC specific cancer phenotypes. Adapted from Witt, O. et
al. 2009 (21).

1.5 Natural Product Biosynthesis by NRPS and PKS Systems
The broad class of natural products (secondary metabolites) has shown to be a
source of new HDAC inhibitors. Natural products are considered to be non-essential to
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the growth and development of bacteria but may provide selective survival advantages.
In bacteria, secondary metabolites are often biosynthesized starting in middle to late
logarithmic growth and into the stationary growth suggesting a physiological role in
survival and maintenance. A majority of secondary metabolites are produced by three
common biosynthetic systems; nonribosomal peptide synthetases (NRPS), polyketide
synthases (PKS) and hybrid NRPS-PKS systems (22).
Natural product biosynthesis from modular NRPS and PKS systems are produced
in a similar “assembly line” fashion where NRPS and PKS multifunctional enzyme
complexes are arranged in modules. Typically, one substrate is added per module over
the biosynthetic pathway with successive substrate addition until the product reaches full
length. The full length product is released by cyclization or hydrolysis. Structure of the
biosynthetic product depends on the number of modules, the nature of substrates
incorporated, accessory enzyme modification and the length of the final product.
Modules are further defined by the individual protein domains with specific function
integrated into the module. The unique nature of the protein domains within the module
dictates the length, substrate specificity and reactions that occur at each module. A
minimal NRPS module is composed of three distinct domains: adenylation (A) domain
responsible for recognizing a specific amino acid substrate and adding it to the thiolation
(T, also known as peptidyl carrier protein, PCP) domain that carries the substrate and
moves it to the condensation (C) domain which is responsible for peptide bond formation
between two successive substrates. In contrast, a minimal PKS module consists of
domains performing analogous functions to the NRPS module. It consists of an acyl
transferase (AT) domain similar to A domain that determines acyl-CoA substrate
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specificity, a thiolation (T, also known as acyl carrier protein, ACP) domain, and
ketosynthase (KS) domain catalyzing the formation of a C-C bond through a claisen
condensation reaction between successive substrates (22,23). The hybrid NRPS-PKS
system combine modules from each biosynthetic system connected by thiolation domains
that allow the addition of substrates by upstream KS or C domains.
A requirement for all PKS and NRPS biosynthetic pathways is the conversion of
the apo-carrier proteins, ACP and PCP respectively, to the active holo form through the
attachment of a 4’-phosphopantetheinate (Ppant) prosthetic group. The transfer of the
prosthetic group is catalyzed by a family of Mg2+ dependent 4’-phosphopantetheinyl
transferases to a conserved serine within the consensus sequence GX(D/E/H)S motif on
the ACP/PCP (24, 25). The newly introduced thiol (-SH) group of the Ppant prosthetic
group acts as a nucleophile for acylation by a substrate, which may be acyl-CoA or
malonyl-CoA derivatives for the fatty acid and PKS, or aminoacyl-AMPs for the peptide
and depsipeptide synthetases. Therefore, the Ppant modification is a critical feature
required by both NRPS and PKS modules that allows substrates to be tethered to a carrier
protein (PCP or ACP) via a thioester bond.
The mechanism of chain elongation of both NRPS and PKS systems occurs in an
assembly line fashion while substrates are bound as thioesters to the carrier protein. In
NRPS systems, the nucleophilic attack from the downstream aminoacyl-S-T on the
upstream peptidyl-S-PCP results in chain elongation at that condensation domain between
the modules. While in PKS systems, nucleophilic attack from the downstream thioester
enolate on the upstream acyl-S-ACP leads to chain elongation by the upstream KS
domain. Therefore in accordance with the colinearity rule, the number of modules in an
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enzymatic assembly line of NRPS and PKS systems usually determines the chain length
and the identity of the module A or AT domains define the substrates incorporated. The
identification of the substrates by A and AT domains dictates the structure of the
secondary metabolite. Once the biosynthetic product reaches its full length, it can either
be cyclized or hydrolyzed by a (type I) terminal thioesterase (TE) to release the product.
In many secondary metabolite biosynthetic systems, tailoring reactions or post
biosynthetic modifications like glycosylation, hydroxylation and oxidative cyclization
occur after assembly line synthesis while in other systems the presence of embedded
accessory domains may modify the final structure of the natural product (22, 23).
Interestingly, PKS domains share an ancestral relationship to fatty acid
biosynthetic domains and the PKS core domain structure can be modified to possess
similar tailoring enzymes. The fatty acid biosynthesis pathway consists of a core set of
enzymes including a ketosynthase (KS), an acyl carrier protein (ACP), a keto-reductase
(KR), a dehydrogenase (DH), enoyl reductase (ER), an acetyl-CoA acyl transferase (AT),
and a malonyl-CoA:ACP acyl transferase (MAT). In comparison to the minimal PKS
domains consisting of a ketosynthase (KS), acyl carrier protein (ACP) and an acyl
transferase (AT/MAT) for complete polyketide biosynthesis, the polyketide intermediates
can also be modified by tailoring enzymes derived within the PKS gene cluster or from
fatty acid biosynthesis, such as KRs, DHs, ERs, aromatases (AROs), and cyclases
(CYCs) to yield a diverse array of natural products (26). Additional modifications by
other tailoring enzymes such as dimerases, P450 monooxygenases, methyltransferases,
and glycosyltransferases can further elaborate the structure of the natural product. New
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modifications can contribute to significantly increase structure diversity and function of a
molecule and has been shown to increase antibiotic activity (27).
Whereas the NRPS and PKS multimodular and multienzyme assembly lines
produce nonribosomal peptides and polyketides respectively, there are also examples of
mixed NRPS-PKS systems in nature which biosynthesize hybrid NRPS-PKS natural
products. The modular structure of NRPS and PKS biosynthetic systems and the
compatible chemistry at the NRPS-PKS interface permits the biosynthesis of these hybrid
natural products (22, 23).
The dedicated function of biosynthetic pathways requires their streamlined
genetic organization and this may reflect their coordinated regulation. Thus it is not
surprising that genes required for the biosynthesis, tailoring and export of natural
products are usually clustered (28, 29).

1.6 Discovery and Bioactivities of the Natural Product FK228 as an HDAC Inhibitor
The search for new cyclic depsipeptides with increased anticancer activities
shows great promise for epigenetic anticancer treatment (17, 30, 31, 32). The FK228family of class specific HDAC inhibitors, consisting of FK228, thailandepsins and
spiruchostatins, are natural products produced by Gram-negative bacteria. The function
of cyclic depsipeptide within these bacteria is not clearly understood. The characteristic
features of the FK228-family of compounds contain a bicyclic depsipeptide architecture,
presence of an ester linkage (depsipeptide bond) and a disulfide bond to close the second
ring structure (Figure 3).
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Figure 3. Structures of FK228-family of HDAC inhibitors. (A) FK228, (B)
Spiruchostatin A (R=CH3) and Spiruchostatin B (R=CH2CH3), (C) Thailandepsin A
(R=SCH3) and Thailandepsin B (R= CH2CH3).

FK228 was discovered as a fermentation product of Chromobacterium violaceum
no. 968, a Gram-negative cocco-bacillus opportunistic pathogen. Furumai discovered
FK228 while screening for agents that could reverse malignant phenotype of Ha-ras cells
to normal (33). In addition to significant anticancer activity against a variety of cell lines,
FK228 also showed weak antibiotic activities (30, 33). FK228 exists in two forms. First,
it acts as an inactive prodrug with its intact disulfide bond to diffuse across membranes.
This is a key property that affects its bioavailability. Upon entry into the cell, intracellular
reduction of the disulfide bond results in the formation of the active form with free
sulfhydryl groups that can react with the active site zinc of class I HDACs (30). HDAC
inhibition ultimately results in a cascade of cellular changes that produce the anticancer
effects and regression of cancer (34). Furthermore, FK228 was granted FDA approval
for the treatment of cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma
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(PTCL). This signifies the important role of cyclic depsipeptides in anticancer therapy
and validates research towards developing and engineering structural analogs with
improved therapeutic properties (34).

1.7 Discovery and Function of Cell Penetrating Peptides
Cell-penetrating peptides (CPPs) are composed of relatively short basic peptides
of 5 to 40 amino acids and possess the ability to cross the cell membrane through a
number of mechanisms. The membrane translocation process appears to be dependent on
the cell type and the cargo that may be conjugated to the CPP (35). Recent studies
suggest that most CPPs enter eukaryotic cells through endocytosis uptake mechanisms,
however small arginine-rich CPPs have been shown to cross the plasma membrane in an
energy independent process (36). CPPs can utilize both the clathrin-dependent and
clathrin-independent endocytosis pathways to gain entrance into the cell and are able to
escape from the endosomes to the cytoplasm. Translocation from the endosome appears
to be facilitated by endosome acidification allowing the CPP to cross the lipid bilayer
(35, 37, 38). Recently, YopM, a protein associated with Yersinia enterocolitica infection
was shown to have cell translocation capabilities. Normally, YopM and other pathogenic
proteins are passed through the cell membrane via the type III secretion system. This
activity was attributed to two highly cationic amino acid regions within two alpha helices
in the N-terminus that demonstrated the ability to translocate a fused protein cargo across
the cellular membrane (39).
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Table 1. Common CPP sequences
Names

Sequences

Penetratin
Tat
Transportan
MAP
KALA
P1
MPG
Pep-1
Arg9
hCT

RQIKIWFQNRRMKWKK
GRKKRRQRRRPPQ
GWTLNSAGYLLGKINLKALAALAKKIL
KLALKLALKALKAALKLA
WEAKLAKALAKALAKHLAKALAKALKACEA
MGLGLHLLVLAAALQGAWSQPKKKRKV
GALFLGFLGAAGSTMGAWSQPKKKRKV
KETWWETWWTEWSQPKKKRKV
RRRRRRRRR
LGTYTQDFNKFHTFPQTAIGVGAP

The membrane translocation activity of CPPs and CPP fusion proteins represents
new engineering opportunities with vast therapeutic applications. CPPs have been shown
to deliver a variety of cargo including short inhibiting RNA, plasmids, proteins,
liposomes, drugs and fluorescent markers, and represent a powerful strategy for drug
delivery. This strategy can be used to increase cancer cell activity of these anticancer
agents by facilitating their delivery into tumor cells. Furthermore, the CPP
transmembrane activity showed that drug resistant cancer cells could be reverted back to
a drug sensitive phenotype by conjugating CPP with Taxol and other known anticancer
drugs by increasing intracellular drug concentrations (40). Also, CPPs conjugated with
protein or protein domains can be used to specifically target pathways associated with a
pro-cancer cell state or apoptosis pathways leading to cell death of cancer cells. While
cell targeting with most CPPs is ambiguous, recent studies identified CPPs with tumor
targeting capabilities (41). Finally, fluorescent labeled-CPP conjugates have been
developed for surgical cancer therapy. The fluorescent-CPP with an antibody specific for
the cancer cells facilitates the endosomal escape of the conjugate preserving the
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fluorescent signal within the cancer cell cytoplasm for easy surgical removal of only
tumor tissue. Therefore, these unique peptides offer a variety of engineering options for
the development of new anticancer agents and many other therapeutic applications.

Figure 4. Applications of CPP-cargo constructs. Cell penetrating peptides are capable of
transporting a variety of cargo across the cell membrane. The variety of cargo makes
CPPs a valuable shuttle targeting multiple cellular structures and pathways. These
characteristics have shown valuable in gene silencing, protein delivery, drug delivery and
cellular imaging. Adapted from Koren and Torchilin, 2012 (42).

1.8 Targeting Mitochondrial Apoptosis Pathway for Cancer Therapy
The development of CPP anticancer peptides requires the identification of cellular
targets capable of inducing cell death. The translocation of CPPs to the cancer cell
cytoplasm permits the targeting of the mitochondrial apoptotic pathway or downstream
caspases associated with the death receptor pathway. Normally cell death can be
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induced by the binding of apoptosis-inducing ligands (such as FasL) to specific death
receptors (such as FAS) located at the cell surface. The transmembrane receptor FAS,
contains a cytoplasmic death domain where FADD (Fas-associated death domain) can
bind in presence of FasL, and recruit pro-caspase 8. This recruitment results in the
activation of caspase 8 that initiates caspase 3 activation and subsequent activation of
caspase activated DNase (CAD). Caspase 3 cleaves I-CAD, the inhibitor of CAD
releasing it to enter the nucleus and degrade DNA. Caspase 8 also cleaves Bid protein,
resulting in a truncated Bid (tBid) (43). Upon cleavage, tBid can dimerize with either
Bax or Bad causing the release of cytochrome c from mitochondria (44). However, the
mechanisms leading to mitochondrial membrane disruption and release of pro-apoptotic
factors remain unclear. The disruption of the mitochondrial membrane leads to the
release of cytochrome c, Smac/DIABLO (second mitochondrial-derived activator of
caspase; Diablo: direct IAP-binding protein with low pI), AIF (apoptosis inducing factor)
and procaspases. The inhibitor Bcl2, prevents the release of cytochrome C and AIF in
the cytoplasm. Once in the cytoplasm, cytochrome c binds to Apaf-1 (apoptosis protease
activating factor) forming the apoptosome, which activates caspase 9 and downstream
effector caspases. Smac/DIABLO binds to IAP (inhibitors of apoptosis) and prevent them
from inhibition of the caspase 9 and caspase 3 activation (43). AIF has an indirect role in
chromosome degradation as it activates endonuclease G, a DNase that moves from the
mitochondria to the nucleus during apoptosis. Interestingly to note, the mtDNA is not
fragmented during apoptosis.

19

Figure 5. Death-receptor and mitochondrial apoptosis pathways. Exploration of the two
apoptosis pathways identified a number of intracellular targets to induce apoptosis with
CPP constructs. Adapted from Bayir and Kagan, 2008 (43).
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CHAPTER 2

RECONSTITUTION OF FK228 BIOSYNTHETIC PATHWAY REVEALING CROSSTALK BETWEEN MODULAR POLYKETIDE SYNTHASES AND FATTY ACID
SYNTHASE

Content of this chapter is a reformatted version of Wesener, S. W., Potharla, V. Y., and
Y. Q. Cheng. 2011. Reconstitution of FK228 Biosynthetic Pathway Revealing CrossTalk between Modular Polyketide Synthases and Fatty Acid Synthase. Appl Environ
Microbiol 77: 1501-1507.
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2.1 Abstract
Functional cross-talk between fatty acid biosynthesis and secondary metabolism
has been discovered in several cases in microorganisms, none of them however involves
a modular biosynthetic enzyme. Previously we reported a hybrid modular nonribosomal
peptide synthetase (NRPS)-polyketide synthase (PKS) pathway for the biosynthesis of
FK228 anticancer depsipeptide in Chromobacterium violaceum no. 968. This pathway
contains two PKS modules on the DepBC enzymes that lack a functional acyltransferase
(AT) domain, and no apparent AT-encoding gene exists within the gene cluster or its
vicinity. We report here that, through reconstitution of the FK228 biosynthetic pathway
in E. coli cells, two essential genes, fabD1 and fabD2, both encoding a putative malonyl
CoA acyltransferase component of the fatty acid synthase complex, are positively
identified to be involved in FK228 biosynthesis. Either gene product appears sufficient to
complement the “AT-less” PKS modules on DepBC for polyketide chain elongation.
Concurrently a gene (sfp) encoding a putative Sfp-type phosphopantetheinyltransferase
was identified to be necessary for FK228 biosynthesis as well. Most interestingly,
engineered E. coli strains carrying variable genetic components produced significant
levels of FK228 under both aerobic and anaerobic cultivation conditions. Discovery of
the trans complementation of modular PKSs by housekeeping ATs reveals natural
product biosynthesis diversity. Moreover, demonstration of anaerobic production of
FK228 by an engineered facultative bacterial strain validates our effort toward
engineering of novel tumor-targeting bio-agents.
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2.2 Introduction
Polyketide synthases (PKSs) share many similarities with fatty acid synthases
(FASs) and can be largely classified as type I, II and III, according to their architecture
and mode of catalysis; yet many variants of PKSs exit in nature (5, 27, 29). Type I PKSs
are multifunctional enzymes organized into modules, each of which harbors a set of
distinct domains responsible for the catalysis of one cycle of polyketide chain elongation.
A prototypical type I PKS elongation module contains minimally three integral domains
– a ketosynthase (KS), an acyltransferase (AT) and an acyl carrier protein (ACP) – that
together catalyze one round of polyketide chain elongation. Optional domains (such as
ketoreductase [KR], dehydratase [DH], enoylreductase [ER]) are found between the AT
and ACP domains, which carry out variable steps of reductive modifications on
polyketide intermediate. Type II PKSs are multienzyme complexes that carry a single set
of catalytic domains acting iteratively. Type III PKSs are chalcone synthase (CHS)-like
enzymes that essentially are iteratively acting condensing enzymes. FASs, and type I and
type II PKSs all use ACPs to tether acyl CoA substrates during fatty acid or polyketide
biosynthesis, whereas type III PKSs directly condense acyl CoA substrates without
carrier proteins. Prior to biosynthesis, apo form of ACPs must be activated to holo form
by attaching a 4’-phosphopantetheinyl moiety from CoA onto a conserved serine residue;
this posttranslational modification reaction is catalyzed by
phosphopantetheinyltransferases (PPTases) that can be largely classified into two groups,
AcpS-type and Sfp-type (12, 18, 22).
Integral AT domains in the prototypical type I PKSs were termed cognate ATs
(8). A distinct variant of the type I PKSs contains no intact cognate ATs but a short
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segment of remnant AT sequence in some or all modules. This subclass of type I PKSs
was named the “AT-less” type I PKSs and the remnant AT segment the AT docking
domain (7, 8, 31). The essential AT activities are provided in trans by discrete AT
enzyme encoded by genes that are physically separated from the PKS genes, but
nevertheless within the same gene cluster.

Figure 6. Identification of missing genes necessary for FK228 biosynthesis in
Chromobacterium violaceum no. 968. (A) Local genetic map of two candidate PPTaseencoding genes, with the sfp gene product postulated to participate in
phosphopantetheinylation of carrier proteins of the FK228 biosynthetic pathway. (B)
Local genetic map of three candidate AT-encoding genes, with the fabD1 and fabD2
gene products postulated to provide AT activities to complement the “AT-less” PKS
modules on DepBC proteins for FK228 biosynthesis. (C) Scheme of two “AT-less” PKS
modules on DepBC proteins that require a PPTase for carrier protein
phosphopantetheinylation and a trans AT for polyketide chain elongation in FK228
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biosynthesis. An inactive DH domain is drawn in light gray and labeled as DHi. KS, AT,
ACP, DH, KR and PPTase are standard abbreviations of domain/enzyme names that have
been described in the text.

Our studies of the biosynthesis of FK228, a potent histone deacetylase inhibitor recently
approved by FDA for the treatment of cutaneous T-cell lymphoma (CTCL) (1, 15),
revealed that a 12-gene dep gene cluster encodes a hybrid modular NRPS-PKS pathway
(9, 23), and that an FAD-dependent oxidoreductase is responsible for a critical disulfide
bond formation in FK228 biosynthesis in Chromobacterium violaceum no. 968 (32).
Nevertheless there are still several unanswered questions regarding the FK228
biosynthetic pathway. In particular, the two PKS modules on DepBC enzymes do not
contain any cognate AT domain but a remnant AT docking domain (Fig. 7C), and there is
no AT-encoding gene anywhere in the defined dep gene cluster (9, 23). Where does the
AT activity necessary for FK228 biosynthesis come from? In this work we report the
identification of two essential genes, fabD1 and fabD2, both encoding a putative malonyl
CoA acyltransferase (MCAT; also known as FabD, encoded by the fabD gene)
component of the FAS II complex, that are positively involved in FK228 biosynthesis.
Concurrently we identified a gene (sfp) encoding a putative Sfp-type PPTase necessary
for FK228 biosynthesis as well. Furthermore, we show that, through reconstitution of the
FK228 biosynthesis pathway, FK228 could be produced by recombinant E. coli strains
under both aerobic and anaerobic cultivation conditions. Our studies revealed, for the first
time, that modular PKSs recruit FabD components of the primary metabolism for the
biosynthesis of a secondary metabolite. Discovery of the trans complementation of
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modular PKSs by housekeeping ATs reveals natural product biosynthesis diversity.
Moreover, demonstration of anaerobic production of FK228 by an engineered facultative
bacterial strain validates our effort toward engineering of novel tumor-targeting bioagents (6).

2.3 Materials and Methods

2.3.1 Bacterial strains, plasmids, culture conditions, and general molecular biological
manipulations.
The bacterial strains and plasmids used in this study are listed in Table 1. Culture
conditions and general molecular biological manipulations were performed as described
(9, 32), or according to standard protocols (25).

2.3.2 Rapid genome sequencing and gene identification.

Genomic DNA of the wild type C. violaceum no. 968 strain was prepared from an
overnight culture with an UltraClean Microbial DNA Isolation kit (MO BIO Labs,
Carlsbad, CA), and was submitted for shotgun single-end and paired-end shotgun
sequencing on a G20 FLX platform (454 Life Science, Branford, CT) at the Research
Technology Support Facility of Michigan State University (East Lansing, MI). de novo
assembly of sequence reads by instrument software was performed and resulted in a
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quality draft genome sequence. Candidate genes were identified by using known protein
sequences as bait to search the draft genome sequence of C. violaceum by Blastx
algorithm (3).
2.3.3 General strategies for targeted gene deletion in C. violaceum no. 968.
A multiplex PCR method, as described elsewhere (10, 23, 32), was used for all
intended gene deletion experiments. This method utilized a broad host-range Flp-FRT
recombination system for site-specific gene replacement/deletion and subsequent marker
removal (10, 16). Primers used for making gene deletion constructs and for detection of
genotypes are listed in Table 2.

2.3.3 Reconstitution of FK228 biosynthetic gene cluster in engineered E. coli strains.
To probe whether individual candidate AT-encoding genes or PPTase-encoding
genes are involved in FK228 biosynthesis, a three-plasmid system was utilized for gene
cluster reconstitution and FK228 biosynthesis in bacterial strains derived from E. coli
BL21(DE3) (Fig. 7A). First, all candidate genes were amplified by high fidelity PCR
from the genomic DNA of C. violaceum with primer sets carrying designed restriction
sites. Second, two candidate PPTase-encoding gene amplicons were double-digested with
BamHI/HindIII and individually cloned into the first multiple cloning site (MCS) of
pCDFDuet-1 (Novagen, Madison, WI) to create two intermediate constructs, pCDFDuet1-acpS and pCDFDuet-1-sfp. Third, two candidate AT-encoding gene amplicons were
double-digested with NdeI/KpnI and individually cloned into the second multiple cloning
site of pCDFDuet-1 to generate pCDFDuet-1-fabD1 and pCDFDuet-1-fabD2, or into the
two previously made intermediate constructs to create a combination of 4 final
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constructs, pCDFDuet-1-acpS-fabD1, pCDFDuet-1-acpS-fabD2, pCDFDuet-1-sfpfabD1, pCDFDuet-1-sfp-fabD2 (Table 1). Finally, the Cosmid 18, which carries the
original incomplete FK228 biosynthetic gene cluster that lacks any AT-encoding gene or
PPTase-encoding gene (9), and pBMTL-3-depR, which was created to complement a
depR-deletion mutant of C. violaceum (23), were used in combination with the above
expression constructs for the transformation of E. coli BL21(DE3) cells to create a series
of bacterial strains (Table 2). Kanamycin at 25 µg/ml, chloramphenicol at 25 µg/ml, and
streptomycin at 25 µg/ml were used individually or in combination for selection and
maintenance of respective E. coli strains.
2.3.4 Bacterial fermentation and quantification of FK228 production by liquid
chromatography-mass spectrometry (LC-MS).
Wild type C. violaceum strain and recombinant E. coli strains were fermented
aerobically for 4 days at 30ºC under constant agitation (200 rpm) in 50 ml of LB media
supplemented with 1% (w/v) Diaion HP-20 resin (Sigma-Aldrich, St. Louis, MO) and
appropriate antibiotics where necessary. Gene expression was induced with 0.5% (w/v)
lactose and 0.1 mM IPTG when bacterial culture reached an OD600 of 0.4. Strict
anaerobic fermentation of bacterial strains was carried out similarly for 5 days at room
temperature in a Coy anaerobic chamber (Grass Lake, MI) with occasional manual
agitation, except for that 0.05% (w/v) thioglycolate was added to the media to capture
any oxidative species generated during fermentation. Extraction of metabolites, and
detection and quantification of FK228 by LC-MS were performed as described (23).

2.3.5 RNA extraction and reverse transcription (RT)-PCR.
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Recombinant E. coli BL21(DE3) strains were grown in LB media supplemented
with appropriate antibiotics at 30ºC under constant agitation (200 rpm) to an OD600 of
0.4. Five ml of each pre-induction sample was collected and the remaining cultures were
induced with 0.5% (v/v) lactose and 0.1 mM IPTG. Aliquots of sample were collected at
60 min and again at 120 min post induction. Preservation of sample aliquots, extraction
of total RNA, and RT-PCR experiments were performed as described (23). Primers used
for detection of individual gene expression are listed in Table 4.

2.3.6 Nucleotide sequence accession numbers.
The nucleotide sequences of C. violaceum no. 968 genes reported in this paper
have been deposited in the GenBank database under accession numbers HM449690 for
16S rRNA gene, HM449691 for fabD1, HM449692 for fabD2, HM449693 for AT3,
HM449694 for acpS, and HM449695 for sfp, respectively.

2.4.1 Results

2.4.2 Draft genome sequencing of Chromobacterium violaceum no. 968.
Shotgun sequencing of C. violaceum genomic DNA on a GS20 FLX Sequencer
generated a total of 163,954,650 input bases, which were assembled into 122 contigs;
among them 82 are large contigs (>500 nt) with an average contig size of 59,514 bps.
Those contigs were further aligned into 15 scaffolds with a total length of 4,909,141 bps.
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The sequence coverage for this draft bacterial genome was thus calculated at 33.4 folds,
which exceeded the desired 30-fold oversampling of raw sequence for the 454
pyrosequencing and de novo assembly technology platform (13). Compared to the
published 4.75-Mb complete genome of a type strain of C. violaceum ATCC 12472 with
a (G + C) content of 64.8% (11), the 4.91-Mb draft genome sequence of C. violaceum no.
968 with an overall (G + C) content of 61.9% obtained in this study appears to be near
complete. The quality of this draft genome sequence was assessed by the following
analyses. First, a comparison of the 16S rDNA sequences of two C. violaceum strains
revealed an overall 96% identity without a single gap (Fig. 9), indicating a high quality of
the draft genome sequence and a taxonomical relatedness of the two strains. Second, a
homology search by Blastn algorithm of the draft genome sequence using our previously
published FK228 biosynthetic gene cluster sequence (GenBank no. EF210776) (9) as bait
identified two contigs that carry the gene cluster with a 100% sequence identify and with
a 1298-bp sequence gap (data not shown). This gap was artificially created due to two
highly homologous regions within the gene cluster that were assembled into a single copy
of sequence.

2.4.3 Identification and initial characterization of candidate genes.
Sequences of three bait proteins, FabD of E. coli K-12 (GenBank no.
AAC74176), FabD of C. violaceum ATCC 12472 (GenBank no. NP_903085) and LnmG
of Streptomyces atroolivaceus S-140 (GenBank no. AAN85520), were used to search the
draft genome sequence and identified three candidate genes, fabD1, fabD2 and AT3, that
encode putative AT enzymes (FabD, MCAT or AT) (Table 3; Fig. 7B). Based on
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bioinformatic analysis, the fabD1 gene lies within an apparent FAS II gene cluster that
also includes fabH, fabG, acp and fabF, whereas fabD2 is a standalone gene whose
function cannot be predicted a priori. The AT3 gene lies within a putative gene cluster
that may be involved in cell-surface O-antigen biosynthesis.
Similarly, sequences of five bait proteins, AcpS of E. coli K-12 (GenBank no.
P24224), Sfp of Bacillus subtilis (GenBank no. P39135), AcpS of C. violaceum ATCC
12472 (GenBank no. NP_901742), EntD of C. violaceum ATCC 12472 (GenBank no.
NP_902320) and PcpS of Pseudomonas aeruginosa PAO1 (GenBank no. AAG04554),
were used to search the draft genome sequence and identified two candidate genes, acpS
and sfp, that encode putative PPTase enzymes (AcpS; Sfp) (Table 3; Fig. 7A). The acpS
gene appears to be a standalone gene likely involved in primary metabolite (e.g. fatty
acid) biosynthesis. The sfp gene is located at the end of an apparent NRPS gene cluster,
therefore it is likely involved in secondary metabolite (e.g. nonribosomal peptide or
hybrid molecule) biosynthesis.
Individual candidate genes were subjected to targeted gene deletion by a wellestablished multiplex PCR procedure to probe whether they play any roles in FK228
biosynthesis. Only AT3 was successfully mutated and the mutant strain did not show any
notable difference from the wild type strain (data not shown), suggesting that AT3 is
disposable and is independent of FK228 biosynthesis. Thus AT3 was not further tested. In
contrast, four other candidate genes, fabD1, fabD2, acpS and sfp, could not be mutated
despite numerous attempts, indicating that they are all essential to the bacterial
physiology and survival. They were then subjected to tests by a different strategy
described below.
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2.4.4 Reconstitution of the FK228 biosynthetic pathway in E. coli.
A series of recombinant E. coli strains were created herein (Table 2; Fig. 7A) and
the relative levels of FK228 production by these strains were examined by LC-MS (Fig.
8; Table 5 and Fig. 10). When Cosmid 18, the originally identified large construct that
carries the dep gene cluster which definitely lacks an AT-encoding gene and a PPTaseencoding gene (9), was introduced into E. coli BL21(DE3) cells, the recombinant strain
SW01 failed to produce FK228. When a newly defined pathway regulatory gene, depR
(23), was introduced into SW01 via a broad-host range construct pBMTL-3-depR, the
resulting strain SW02 still did not produce any detectable level of FK228. When the
candidate sfp gene was introduced into SW02 via a compatible construct pCDFDuet-1sfp, the resulting strain SW03 produced a moderate level of FK228. When either the
candidate fabD1 or fabD2 gene was added in tandem with sfp on pCDFDuet-1-sfp-fabD1
or pCDFDuet-1-sfp-fabD2 construct, the resulting strains of SW07 and SW08 produced
significant levels of FK228. All other strains that received a single candidate gene of
either acpS (strain SW04), fabD1 (strain SW05) or fabD2 (strain SW06), or two genes
with acpS in tandem with either fabD1 (strain SW9) or fabD2 (strain SW10) did not
show production of detectable level of FK228. Those observations led to the following
conclusions: (1) the sfp gene but not the acpS gene is capable of converting all ACPs (and
presumably peptidyl carrier proteins – PCPs) in the FK228 biosynthetic pathway from
their inactive apo form to their active holo form; (2) indigenous E. coli AcpS cannot
promiscuously act on those heterologous carrier proteins from a secondary metabolic
pathway; (3) either gene product of the essential fabD1 or fabD2 gene of C. violaceum
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no. 968 is able to complement the “AT-less” PKS modules on DepBC for polyketide
chain extension; (4) even E. coli FabD (in the background in case of strain SW03) is able
to provide the necessary AT activities for FK228 biosynthesis albeit at a lower rate; and
(5) at this point we believe that genes necessary for FK228 biosynthesis have all been
identified.

2.4.5 RT-PCR verification of gene expression.
To verify whether key biosynthetic and regulatory genes for FK228 biosynthesis
were adequately expressed in the SW07 recombinant strain under normal aerobic
conditions, aliquots of bacterial culture were collected at three time points, total RNA
samples were prepared and subjected to semi-quantitative RT-PCR analysis (Fig. 7B).
Prior to chemical induction, all examined genes including two representative structural
genes (depA and depJ) but excluding the 16S rDNA control were not expressed. This
suggests that the depR gene in its native position on Cosmid 18 is not functioning in E.
coli cells, likely due to a lack of proper external or internal stimulus, or signal
transduction pathway, or other regulatory components; expression of the dep gene cluster
carried by Cosmid 18 in E. coli cells requires an ectopic copy of depR driven by lactoseinducible promoter on a pBMTL-3 vector. Upon induction by lactose and IPTG for the
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Figure 7. Reconstitution of FK228 biosynthesis in E. coli cells. (A) Scheme of a threeplasmid approach for reconstitution of FK228 biosynthetic pathway in E. coli
BL21(DE3) cells. Only one cell containing one copy of each plasmid is drawn into
picture for simplicity. A series of engineered strains were generated with different
combinations of plasmids or different genes on plasmids (Table 2). (B) Examination of
gene expression by semi-quantitative RT-PCR in engineered strain SW07 cultivated
under aerobic conditions. 16S rDNA was amplified as an internal control.

expression of depR from pBMTL-3-depR and for the expression of sfp and fabD1 from
pCDFDuet-1-sfp-fabD1, those genes and two representative structural genes (depA and
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depJ) were found to have expressed at 60 min post induction; and the gene expression
reached higher levels at 120 min post induction.

2.4.6 Production of FK228 under anaerobic fermentation conditions.
As a pilot study toward engineering of novel tumor-targeting bacterial agents that
may effectively infiltrate, multiply and continuously produce an anticancer drug inside
the hypoxic core of solid tumors (6), we examined whether the engineered SW07 strain
may produce FK228 under anaerobic fermentation conditions. To our delight the SW07
strain produced c.a.14.1% as much FK228 as did by the wild type C. violaceum strain or
15.3% by the SW07 strain itself under aerobic conditions (Fig. 8; Table 5 and Fig. 10);
this relative level of FK228 production was translated into 0.40 mg/L of actual yield or
c.a. 741 nM concentration when normalized by FK228 standard. As a control, the wild
type C. violaceum strain was also found to have produced a lower level of FK228 under
anaerobic conditions. This Gram-negative bacterial species appeared to be able to survive
and grow slightly during the first 24 hr under the strict anaerobic conditions tested.
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Figure 8. Levels of FK228 produced by recombinant E. coli strains relative to the wild
type strain of Chromobacterium violaceum no. 968 cultivated under aerobic conditions
unless indicated by * for under anaerobic conditions. Data are mean values of duplicate
experiments with error bars indicating standard deviation. Detailed strain information and
FK228 levels are provided in Table 2 and Table 5.

2.5.1 Discussion
Organizational and functional variation of PKSs leads to diverse structure of
polyketide natural products (5, 27). The modular “AT-less” PKSs represent a severe
deviation from the canonical type I PKSs (7, 8) and this phenomenon appears to be a
transition state of complex enzyme evolution from FAS II to type II PKSs (28).
Nevertheless in most “AT-less” PKS pathways the AT activities required for polyketide
chain elongation are often encoded by discrete genes within the respective biosynthetic
gene clusters. In the present work, for the first time, we uncovered an extreme case of
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“AT-less” PKS system where the AT activity is encoded by fabDs, the essential bacterial
genes involved in fatty acid biosynthesis.
As more and more modular “AT-less” PKSs are identified (7), it was not so
surprising to find that the two PKS modules on DepBC do not contain an intact cognate
AT domain but remnant of AT-docking segment (Fig. 7C). However a failure to identify
any AT-encoding gene within or in the vicinity of the defined dep gene cluster was
intriguing (9, 23). To address the mystery about where the necessary AT activities would
come from, the genome of C. violaceum no. 968 was decoded by a rapid genome
sequencing platform, revealing three candidate genes that may encode the AT activities
for FK228 biosynthesis. However, attempts to identify the exact AT-encoding gene by a
direct gene deletion approach was not successful, because two candidate genes (fabD1
and fabD2) could not be mutated due to their apparent essential roles in bacterial
viability. A third gene (AT3) could be mutated but the mutant did not show any obvious
sign of physiological defect or decrease in FK228 production.
We then engineered a series of recombinant E. coli strains that harbor one to three
compatible vectors that carry either the previously reported incomplete dep gene cluster
or candidate genes identified in this work with three objectives in mind (Fig. 7A). First,
we hoped to identify the missing AT-encoding gene and PPTase-encoding gene
necessary for FK228 biosynthesis. Second, we hoped to reconstitute a functional FK228
biosynthetic pathway in a heterologous host such as E. coli cells. Third, we hoped to
demonstrate that FK228 could be produced by a recombinant E. coli strain under both
aerobic conditions and particularly anaerobic conditions as a pilot experiment for genetic
engineering of novel cancer-targeting bio-agents (6).
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Three engineered E. coli strains, SW03, SW07 and SW08, were subsequently
found to produce variable amounts of FK228 under normal (aerobic) fermentation
conditions. In addition to the Cosmid 18 and the depR gene on a vector, all these three
strains received the sfp gene; while other E. coli strains, regardless of having the acpS
gene or not, did not produce FK228. It was thus clear that the AcpS-type PPTase from
either E. coli host or from C. violaceum cannot activate the carrier proteins from the
FK228 biosynthetic pathway. Therefore it was concluded that the sfp gene, which was
predicted to encode a broad substrate-range Sfp-type PPTase, is involved in FK228
biosynthesis. This PPTase should have other essential function as well, otherwise the sfp
gene could have been mutated in the first place. In addition, two of the three strains,
SW07 and SW08, which also received either fabD1 or fabD2 gene of C. violaceum,
produced much higher levels of FK228 than did by SW03. Those observations suggested
that either fabD1 or fabD2 of C. violaceum is involved in FK228 and their involvement is
interchangeable; it is also possible that both genes are redundantly involved in FK228
biosynthesis. Surprisingly, the indigenous fabD of E. coli appeared to function as well for
FK228 biosynthesis in the SW03 strain which received the sfp gene but not fabD1 or
fabD2.
Sequence alignment of the C. violaceum FabD1 and FabD2, and E . coli FabD
shows that FabD1 and FabD share a much higher amino acid sequence identity than other
two sets of comparison (Fig. 11), suggesting that FabD1 is very likely the housekeeping
FAS II component for bacterial fatty acid biosynthesis. The role of FabD2 is less certain.
Besides a positive role in FK228 biosynthesis, FabD2 should have other essential
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functions; otherwise the fabD2 gene could have been mutated in early experimental
attempts.
Now it is proven that an MCAT component of FAS II is recruited by modular
type I PKS modules on DepBC for FK228 biosynthesis, which establishes a unique
functional cross-talk between bacterial primary metabolism and secondary metabolism,
and adds new evidence to the phenomenon of complex enzyme evolution from FAS II to
type II PKSs (28). Previously two type II PKS systems responsible for the biosynthesis of
actinorhodin (24) or tetracenomycin (4, 14, 30) were found to recruit FabD of FAS II.
Additional variants of cross-talk between bacterial primary metabolism and secondary
metabolism have also been reported. For example, in the biosynthesis of quinoxaline
antibiotics in two Streptomyces strains, an ACP from the primary FAS II is recruited by a
standalone condensation domain of type II NRPS to form an initiation module of the
biosynthetic pathway (26). Furthermore, cross-talk between a type I FAS (FAS I) for
primary metabolism and a secondary FAS I for HC-toxin biosynthesis had also be
postulated in the fungal species Cochliobolus carbonum where only one gene encoding
the -subunit of FAS I was found in the secondary metabolic gene cluster, while the subunit of FAS I necessary for HC-toxin biosynthesis might be recruited from the
primary FAS I (2). Recently an opposite example was reported in the apicidin
biosynthetic pathway in Fusarium semitectum where a gene encoding the -subunit of
FAS I is present in the apicidin biosynthetic gene cluster while the -subunit of FAS I
necessary for apicidin biosynthesis is speculated to be recruited from the primary FAS I
(17).
Lastly, the ability by which the engineered SW07 strain produced 0.4 mg/L of
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actual yield or c.a. 741 nM concentration of FK228 under strict anaerobic conditions is
worth highlighting. This accomplishment represents an important milestone toward the
goal of engineering of tumor-targeting bio-agents (6). The next step will be undertaken to
introduce the FK228 biosynthetic capacity into one or more selected nonpathogenic
anaerobic bacterial species, such as Bifidobacterium longum or Clostridium oncolyticum
(21, 33), so that when the engineered bacteria infiltrate and multiply inside the necrotic
region of solid tumors, FK228 will be produced in situ. Because FK228 is a potent
histone deacetylase inhibitor and a new anticancer drug effective in the lower nM range
(19, 34), the synergistic efforts of bacterial oncolysis of tumor tissue and the anticancer
activity of FK228 could potentially be clinically effective against many types of cancer.

4. 6. Supplementary Figures

Cv_No968_16S_rDNA
Cv_ATCC12472_16S_rDNA

1 AACTGAAGAGTTTGATCCTGGCTCAGATTGAACGCTGGCGGCATGCTTTA 50
1 AACTGAAGAGTTTGATCCTGGCTCAGATTGAACGCTGGCGGCATGCTTTA 50
**************************************************

Cv_No968_16S_rDNA
Cv_ATCC12472_16S_rDNA

51 CACATGCAAGTCGAACGGTAACAGGGTGCTTGCACCGCTGACGAGTGGCG 100
51 CACATGCAAGTCGAACGGTAACAGGGTGCTTGCACCGCTGACGAGTGGCG 100
**************************************************

Cv_No968_16S_rDNA
Cv_ATCC12472_16S_rDNA

101 AACGGGTGAGTAATGCATCGGAATGTACCGTGTAATGGGGGATAGCTCGG 150
101 AACGGGTGAGTAATGCGTCGGAATGTACCGTGTAATGGGGGATAGCTCGG 150
**************** *********************************

Cv_No968_16S_rDNA
Cv_ATCC12472_16S_rDNA

151 CGAAAGCCGGATTAATACCGCATACGCCCTGAGGGGGAAAGTGGGGGACC 200
151 CGAAAGCCGGATTAATACCGCATACGCCCTGAGGGGGAAAGCGGGGGATC 200
***************************************** ****** *

Cv_No968_16S_rDNA
Cv_ATCC12472_16S_rDNA

201 GTAAGGCCTCACGTTATACGAGCAGCCGATGTCTGATTAGCTAGTTGGTG 250
201 GAAAGACCTCGCGTTATACGAGCAGCCGACGTCTGATTAGCTAGTTGGTG 250
* *** **** ****************** ********************

Cv_No968_16S_rDNA
Cv_ATCC12472_16S_rDNA

251 GGGTAAAGGCTCACCAAGGCTTCGATCAGTAGCGGGTCTGAGAGGATGAT 300
251 AGGTAAGAGCTCACCAAGGCGACGATCAGTAGCGGGTCTGAGAGGATGAT 300
***** ************ ****************************

Cv_No968_16S_rDNA
Cv_ATCC12472_16S_rDNA

301 CCGCCACACTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAG 350
301 CCGCCACACTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAG 350
**************************************************

Cv_No968_16S_rDNA
Cv_ATCC12472_16S_rDNA

351 TGGGGAATTTTGGACAATGGGCGCAAGCCTGATCCAGCCATGCCGCGTGT 400
351 TGGGGAATTTTGGACAATGGGGGCAACCCTGATCCAGCCATGCCGCGTGT 400
********************* **** ***********************
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Cv_No968_16S_rDNA
Cv_ATCC12472_16S_rDNA

401 CTGAAGAAGGCCTTCGGGTTGTAAAGGACTTTTGTCCGGGAGCAAATCCC 450
401 CTGAAGAAGGCCTTCGGGTTGTAAAGGACTTTTGTCAGGGAGGAAATCCC 450
************************************ ***** *******

Cv_No968_16S_rDNA
Cv_ATCC12472_16S_rDNA

451 AGTGGTTAATACCTACTGGGGCTGAGAGTACCGGAAGAATAAGCACCGGC 500
451 GCTGGTTAATACCCGGCGGGGATGACAGTACCTGAAGAATAAGCACCGGC 500
***********
**** *** ****** *****************

Cv_No968_16S_rDNA
Cv_ATCC12472_16S_rDNA

501 TAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGTGCAAGCGTTAATCG 550
501 TAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGTGCGAGCGTTAATCG 550
************************************** ***********

Cv_No968_16S_rDNA
Cv_ATCC12472_16S_rDNA

551 GAATTACTGGGCGTAAAGCGTGCGCAGGCGGTTGTGCAAGTCTGATGTGA 600
551 GAATTACTGGGCGTAAAGCGTGCGCAGGCGGTTGTGCAAGTCTGATGTGA 600
**************************************************

Cv_No968_16S_rDNA
Cv_ATCC12472_16S_rDNA

601 AAGCCCCGGGCTTAACCTGGGAACGGCATTGGAGACTGCACGACTAGAGT 650
601 AAGCCCCGGGCTTAACCTGGGAACGGCATTGGAGACTGCACAGCTAGAGT 650
***************************************** *******

Cv_No968_16S_rDNA
Cv_ATCC12472_16S_rDNA

651 GCGTCAGAGGGGGGTAGAATTCCGCGTGTAGCAGTGAAATGCGTAGAGAT 700
651 GCGTCAGAGGGGGGTAGAATTCCACGTGTAGCAGTGAAATGCGTAGAGAT 700
*********************** **************************

Cv_No968_16S_rDNA
Cv_ATCC12472_16S_rDNA

701 GCGGAGGAATACCGATGGCGAAGGCAGCCCCCTGGGATGACACTGACGCT 750
701 GTGGAGGAATACCGATGGCGAAGGCAGCCCCCTGGGATGACACTGACGCT 750
* ************************************************

Cv_No968_16S_rDNA
Cv_ATCC12472_16S_rDNA

751 CATGCACGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGTAGTCCA 800
751 CATGCACGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGTAGTCCA 800
**************************************************

Cv_No968_16S_rDNA
Cv_ATCC12472_16S_rDNA

801 CGCCCTAAACGATGTCAACTAGCTGTTGGGGGTTTGAATCCTTGGTAGCG 850
801 CGCCCTAAACGATGTCAACTAGCTGTTGGGGGTTTGAATCCTTGGTAGCG 850
**************************************************

Cv_No968_16S_rDNA
Cv_ATCC12472_16S_rDNA

851 AAGCTAACGCGAGAAGTTGACCGCCTGGGGAGTACGGCCGCAAGGTTAAA 900
851 TAGCTAACGCGTGAAGTTGACCGCCTGGGGAGTACGGCCGCAAGGTTAAA 900
********** **************************************

Cv_No968_16S_rDNA
Cv_ATCC12472_16S_rDNA

901 ACTCAAAGGAATTGACGGGGACCCGCACAAGCGGTGGATGATGTGGATTA 950
901 ACTCAAAGGAATTGACGGGGACCCGCACAAGCGGTGGATGATGTGGATTA 950
**************************************************

Cv_No968_16S_rDNA
Cv_ATCC12472_16S_rDNA

951 ATTCGATGCAACGCGAAAAACCTTACCTGGTCTTGACATGTAACGAACGC 1000
951 ATTCGATGCAACGCGAAAAACCTTACCTGCTCTTGACATGTACGGAACTT 1000
***************************** ************ ****

Cv_No968_16S_rDNA
Cv_ATCC12472_16S_rDNA

1001 CGCAGAGATGTGGTGGTGCCCGAAAGGGAGCGTTAACACAGGTGCTGCAT 1050
1001 GCCAGAGATGGCTTGGTGCCCGAAAGGGAGCCGTAACACAGGTGCTGCAT 1050
********
****************** *****************

Cv_No968_16S_rDNA
Cv_ATCC12472_16S_rDNA

1051 GGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAG 1100
1051 GGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAG 1100
**************************************************

Cv_No968_16S_rDNA
Cv_ATCC12472_16S_rDNA

1101 CGCAACCCTTGCCATTAGTTGCCATCATTAAGTTGGGCACTCTAATGGGA 1150
1101 CGCAACCCTTGTCATTAGTTGCCATCATTCAGTTGGGCACTCTAATGAGA 1150
*********** ***************** ***************** **

Cv_No968_16S_rDNA
Cv_ATCC12472_16S_rDNA

1151 CTGCCGGTGACAAACCGGAGGAAGGTGGGGATGACGTCAAGTCCTCATGG 1200
1151 CTGCCGGTGACAAACCGGAGGAAGGTGGGGATGACGTCAAGTCCTCATGG 1200
**************************************************

Cv_No968_16S_rDNA
Cv_ATCC12472_16S_rDNA

1201 CCCTTATGACCAGGGCTTCACACGTCATACAATGGTCGGTACAGAGGGTC 1250
1201 CCCTTATGAGCAGGGCTTCACACGTCATACAATGGTCGGTACAGAGGGTT 1250
********* ***************************************

Cv_No968_16S_rDNA
Cv_ATCC12472_16S_rDNA

1251 GCGAAGCCGCGAGGTGGAGCCAATCTCATAAAACCGATCGTAGTCCGGAT 1300
1251 GCCAAGCCGCGAGGTGGAGCTAATCTCAGAAAACCGATCGTAGTCCGGAT 1300
** ***************** ******* *********************
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Cv_No968_16S_rDNA
Cv_ATCC12472_16S_rDNA

1301 CGCACTCTGCAACTCGAGTGCGTGAAGTCGGAATCGCTAGTAATCGCAGA 1350
1301 CGCACTCTGCAACTCGAGTGCGTGAAGTCGGAATCGCTAGTAATCGCAGA 1350
**************************************************

Cv_No968_16S_rDNA
Cv_ATCC12472_16S_rDNA

1351 TCAGCATGCTGCGGTGAATACGTTCCCGGGTCTTGTACACACCGCCCGTC 1400
1351 TCAGCATGCTGCGGTGAATACGTTCCCGGGTCTTGTACACACCGCCCGTC 1400
**************************************************

Cv_No968_16S_rDNA
Cv_ATCC12472_16S_rDNA

1401 ACACCATGGGAGTGAGTTTCACCAGAAGTGGGTAGGCTAACCGTAAGGAG 1450
1401 ACACCATGGGAGTGAGTTTCACCAGAAGTGGGTAGGCTAACCGCAAGGAG 1450
******************************************* ******

Cv_No968_16S_rDNA
Cv_ATCC12472_16S_rDNA

1451 GCCGCTTACCACGGTGGGATTCAT 1474
1451 GCCGCTTACCACGGTGGGATTCAT 1474
************************

Figure 9. Alignment of 16S rDNA sequences of Chromobacterium violaceum no. 968
(GenBank no. HM449690; result of the current work) and Chromobacterium violaceum
ATCC 12472 (GenBank no. AE016825) by CLUSTAL W showing 96% sequence
identity and without any gap between the two sequences.
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Figure 10. Examination and quantification of FK228 production by LC-MS. A, strain
Cv WT; B, strain Cv WT under anaerobic conditions; C, strain BL21(DE3); D, strain
SW01; E, strain SW02; F, strain SW03; G, strain SW04; H, strain SW05; I, strain SW06;
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J, strain SW07; K, strain SW07 under anaerobic conditions; L, strain SW08; M, strain
SW09; N, strain SW10. Detailed strain information is listed in Table 2.

Figure 11. Alignment of FabD sequences of Chromobacterium violaceum no. 968
(GenBank no. HM449691 for FabD1, GenBank no. HM449692 for FabD2; result of the
current work) and Escherichia coli BL21(DE3) FabD (GenBank no.ACT42983) by
CLUSTAL W.
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TABLE 2. Bacterial strains and plasmids used in this study
Source or
Strains or plasmids

Description

a

reference

Chromobacterium
violaceum

r

Wild type strain, FK228-producing, Ap Thio

r

b

IPOD

no. 968 (=FERM BP-1968)
Escherichia coli
DH5

General cloning host

Lab stock

S17-1

Host strain for interspecies conjugation

Lab stock

BL21(DE3)

Host strain for heterologous gene expression

Novagen

SW01

BL21(DE3) harboring Cosmid 18

This work

SW02

BL21(DE3) harboring Cosmid 18 and pBMTL-3-depR

This work

SW03

BL21(DE3) harboring Cosmid 18, pBMTL-3-depR and

This work

pCDFDuet-1-sfp
SW04

BL21(DE3) harboring Cosmid 18, pBMTL-3-depR and

This work

pCDFDuet-1-acpS
SW05

BL21(DE3) harboring Cosmid 18, pBMTL-3-depR and

This work

pCDFDuet-1-fabD1
SW06

BL21(DE3) harboring Cosmid 18, pBMTL-3-depR and

This work

pCDFDuet-1-fabD2
SW07

BL21(DE3) harboring Cosmid 18, pBMTL-3-depR and

This work

pCDFDuet-1-sfp-fabD1
SW08

BL21(DE3) harboring Cosmid 18, pBMTL-3-depR and

This work

pCDFDuet-1-sfp-fabD2
SW09

BL21(DE3) harboring Cosmid 18, pBMTL-3-depR and

This work

pCDFDuet-1-acpS-fabD1
SW10

BL21(DE3) harboring Cosmid 18, pBMTL-3-depR and

This work

pCDFDuet-1-acpS-fabD2
Plasmids
pGEM-3Zf

r

Promega

r

Promega

Ap , general cloning vector

pGEM-T Easy

Ap , general cloning vector

Cosmid 18

Ap , Kan , cosmid clone containing the FK228 biosynthetic

r

r

(9)

gene cluster (dep) and flanking DNAs, shotgun sequenced
pBMTL-3

r

Cm , pBBR1 ori, broad host-range vector

(20)
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r

(23)

Sm , CDF ori, dual expression vector

r

Novagen

pCDFDuet-1-sfp

sfp cloned into the MCS1 region of pCDFDuet-1

This study

pCDFDuet-1-acpS

acpS cloned into MCS1 region of pCDFDuet-1

This study

pCDFDuet-1-fabD1

fabD1 cloned into MCS2 region of pCDFDuet-1

This study

pCDFDuet-1-fabD2

fabD2 cloned into MCS2 region of pCDFDuet-1

This study

pCDFDuet-1-sfp-fabD1

sfp cloned into MCS1, fabD1 cloned into MCS2 of

This study

pCDFDuet-1-sfp-fabD2

pCDFDuet-1

This study

pCDFDuet-1-acpS-fabD1

sfp cloned into MCS1, fabD2 cloned into MCS2 of

This study

pCDFDuet-1-acpS-fabD2

pCDFDuet-1

This study

pBMTL-3-depR

Cm , depR (with RBS from pET29a) cloned into pBMTL-3

pCDFDuet-1

acpS cloned into MCS1, fabD1 cloned into MCS2 of
pCDFDuet-1
acpS cloned into MCS1, fabD2 cloned into MCS2 of
pCDFDuet-1

a

Apr, ampicillin resistance; Cmr, chloramphenicol resistance; Kanr, kanamycin

resistance; Smr, streptomycin resistance; Thior, thiostrepton resistance; MCS, multiple
cloning site.
b

IPOD, International Patent Organism Depositary, Tsukuba, Japan.
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TABLE 3. Candidate genes identified through rapid genome sequencing and their
involvement in FK228 biosynthesis
Gene Namea

Deduced Product and Predicted

Gene

Involvement in

Function

Disposability

FK228
Biosynthesis

AT-encoding genes
fabD1

FabD1, likely involved in fatty acid

No

Positive

biosynthesis
fabD2

FabD2, function unpredictable a priori

No

Positive

AT3

AT3, likely involved in cell-surface O-

Yes

No

No

No

No

Yes

antigen biosynthesis
PPTase-encoding
genes

AcpS-type PPTase, likely involved in
acpS

primary metabolite biosynthesis
Sfp-type PPTase, likely involved in

sfp
a

secondary metabolite biosynthesis

AT, acyltransferase; PPTase, phosphopantetheinyltransferase.

TABLE 4. Primers used for gene deletion, genotype detection and detection of gene
expression
Name (primers sorted
by gene)
KpnI-NdeI-fabD1UpF
FRT-F-fabD1-UpR
FRT-R-fabD1-DnF
BamHI-fabD1-DnR
fabD1-RT-PCR-FP
fabD1-RT-PCR-RP
KpnI-NdeI-fabD2UpF
FRT-F-fabD2-UpR
FRT-R-fabD2-DnF
HindIII-fabD2-DnR
fabD2-RT-PCR-FP
fabD2-RT-PCR-RP

Sequence (5’  3’)a
AGGTACCCATATGgcgtttgcatttctgttcc
TCAGAGCGCTTTTGAAGCTAATTCGtt
caactcctgccaggcc
AGGAACTTCAAGATCCCCAATTCGcca
gctacaccgagcc
CTGGATCCtcagttcagttcgccgcgag
(Same as KpnI-NdeI-fabD1-UpF)
(Same as FRT-F-fabD1-UpR)
AGGTACCCATATGctgcgccgcttgccgaa
TCAGAGCGCTTTTGAAGCTAATTCGat
ggaaagccccgccac
AGGAACTTCAAGATCCCCAATTCGcgt
gggaacgcggcatg
CTAAGCTTcatgtaccacttgaccattcc
(Same as KpnI-NdeI-fabD2-UpF)
(Same as FRT-F-fabD2-UpR)

Gene
Deletion
Not
successful

Not
successful
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KpnI-NdeI-AT3-UpF
FRT-F-AT3-UpR
FRT-R-AT3-DnF
BamHI-AT3-DnR
AT3-RT-PCR-FP
AT3-RT-PCR-RP

KpnI-NdeI-acpS-UpF
FRT-F-acpS-UpR
FRT-R-acpS-DnF
HindIII-acpS-DnR
acpS-RT-PCR-FP
acpS-RT-PCR-RP

KpnI-NdeI-sfp-UpF
FRT-F-sfp-UpR
FRT-R-sfp-DnF
HindIII-sfp-DnR
sfp-RT-PCR-FP
sfpRT-PCR-RP

16S-RT-PCR-F
16S-RT-PCR-R
depA-RT-PCR-F
depA-RT-PCR-R
depJ-RT-PCR-F
depJ-RT-PCR-R
depR-RT-PCR-F
depR-RT-PCR-R
a

AGGTACCCATATGgcgtttgcatttctgttcc
TCAGAGCGCTTTTGAAGCTAATTCGc
gtagaatgccttgaagtc
AGGAACTTCAAGATCCCCAATTCGtcg
cctgcaaattgttcag
CTGGATCCttagcgttcggcgcttcttgc
(Same as KpnI-NdeI-AT3-UpF)
(Same as FRT-F-AT3-UpR)
AGGTACCCATATGatttacggcattggcactg
TCAGAGCGCTTTTGAAGCTAATTCGa
aacgcttggccaggaag
AGGAACTTCAAGATCCCCAATTCGctt
agccccgaattggaag
CTAAGCTTctagccgggcgcggagcg
(Same as KpnI-NdeI-acpS-UpF)
(Same as FRT-F-acpS-UpR)
AGGTACCCATATGgaactgaacgctttgatcaag
TCAGAGCGCTTTTGAAGCTAATTCGc
caacagccgtcgtagtg
AGGAACTTCAAGATCCCCAATTCGga
gcagaccttgctgcc
CTAAGCTTcagccctccgcccaggc
(Same as KpnI-NdeI-sfp-UpF)
(Same as FRT-F-sfp-UpR)
gactcctacgggaggcagc
gtattaccgcggctgctggc
cacctcggggtccacgcg
gggaaaaccgcattgcaaggg
tgctttccgtatgcgggcgg
ctcgcgcccatgctgtgccc
gaacttcgctatatcgtcgcg
gctgcgattgctcgatgatgc

Successful

Not
successful

Not
successful

N/A
N/A
N/A
N/A

Sequences in capital letters are designed either to provide restriction sites (underlined)

for directional cloning, or to provide extra base(s) in front of restriction sites for efficient
restriction enzyme digestion, or to provide overlapping sequences for FRT cassette
assembly during multiplex PCR. Lower-case letters indicate gene-specific sequences
used for amplification of individual genes.
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Table 5. Quantification of FK228 production by recombinant E. coli strains relative to the
wild type strain of Chromobacterium violaceum no. 968 cultivated under aerobic conditions
unless indicated by * for under anaerobic conditions. Experiments were performed in
duplicate and the data are presented as mean values with standard deviation.

Strains

Chromobacterium
violaceum
no. 968 (=FERM BP-1968)
no. 968*
Escherichia coli
SW01
SW02
SW03
SW04
SW05
SW06
SW07
SW07*
SW08
SW09
SW10

Descriptiona

Wild type, FK228 producing
(Same as above)

BL21(DE3) harboring Cosmid 18
BL21(DE3) harboring Cosmid 18 and pBMTL-3depR
BL21(DE3) harboring Cosmid 18, pBMTL-3-depR
and pCDFDuet-1-sfp
BL21(DE3) harboring Cosmid 18, pBMTL-3-depR
and pCDFDuet-1-acpS
BL21(DE3) harboring Cosmid 18, pBMTL-3-depR
and pCDFDuet-1-fabD1
BL21(DE3) harboring Cosmid 18, pBMTL-3-depR
and pCDFDuet-1-fabD2
BL21(DE3) harboring Cosmid 18, pBMTL-3-depR
and pCDFDuet-1-sfp-fabD1
(Same as above)
BL21(DE3) harboring Cosmid 18, pBMTL-3-depR
and pCDFDuet-1-sfp-fabD2
BL21(DE3) harboring Cosmid 18, pBMTL-3-depR
and pCDFDuet-1-acpS-fabD1
BL21(DE3) harboring Cosmid 18, pBMTL-3-depR
and pCDFDuet-1-acpS-fabD2

Relative level
of FK228
Production
(%)
100.0
6.76.2
0.0
0.0
46.310.2
0.0
0.0
0.0
92.25.8
14.18.4
86.310.1
0.0
0.0
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CHAPTER 3

ENGINEERING A NOVEL SECRETION SYSTEM FOR PRODUCTION AND
DIRECT PURIFICATION OF ANTICANCER CELL PENETRATING PEPTIDES
FROM THE MEDIA

Content of this chapter is a reformatted version of a manuscript to be submitted to the
journal of Applied and Environmental Microbiology.
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3.1. Abstract
Cell penetrating peptides (CPPs) are short peptides that possess the unique
capacity to translocate across cell membranes. Recently, a CPP derived from a virulence
protein associated with the type III secretion system of Yersinia enterocolitica was
identified and shown to be important in bacterial pathogenicity. Here, we show the
construction of a fusion protein combining the transmembrane activity of a bacterial CPP
with a eukaryotic mitochondrial disrupting protein (MDP) to produce a new CPP-MDP
protein with anticancer activity. We also show the creation of a new E. coli BL21(DE3)based expression system that facilitates the secretion of CPP fusion proteins into the
growth media for rapid and efficient protein purification. This protein secretion system
utilizes induced L-form bacterial spheroplasts to generate a yield of 32 mg/L of CPPMDP directly from the media. Construction of an L-form based E. coli BL21 (DE3)
protein secretion system and a modular CPP expression system allows future rapid CPPfusion protein production with new fusion protein partners to develop new CPP-based
anticancer agents.
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3.2. Introduction
Protein secretion directly into the surrounding growth media offers many
advantages for recombinant protein production. However, traditional laboratory strains
of E. coli do not typically secrete proteins prompting development of new strategies for
protein secretion. Currently, four strategies have been developed to release recombinant
proteins into the media. The first involves the engineering of pathogenic strains of E. coli
to link recombinant protein expression with one of the six dedicated protein secretion
pathways, with the Type I secretion pathway most often targeted (1). The second
strategy involves the use of carrier proteins like the IgG binding domain fused with
recombinant protein A, but the mechanism for release is unknown (2). The third strategy
exploits cell wall structural deficits produced by mutations targeting the gene regulating
cell wall biosynthesis and division (3). One drawback to this approach is the decrease in
cell growth limiting the overall protein production. Finally, the fourth strategy involves
cell lysis through the co-expression of Kil protein with the recombinant protein (4).
However, this strategy utilizing cell membrane disruption lowers the cell density and
does not insure the proper folding of recombinant proteins.
One of the major inhibitors of recombinant protein secretion in E. coli is the
presence of the cell wall. While not critical for cell survival, the bacterial cell wall plays
many important roles in a bacterial growth and survival. Not only is the cell wall
important in protection, but also functions in cell morphology, cellular adhesion and cell
to cell communication. However, under certain circumstances bacteria will lose all or
part of their cell wall producing osmo-sensitive variants. These cell wall defective
bacteria (CWDB) can be generated in vitro and in vivo in many species and has been
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suggested to be a survival strategy utilized by bacteria to negate cell wall-targeting
antibiotics and evade recognition by the immune system (5,6). CWDB can be classified
into four groups (stable vs. unstable, spheroplast vs. protoplast) based on their ability to
grow on specialized osmotically balanced media (7). Stable L form bacteria are formed
through genetic mutation resulting in a physiologically different offspring incapable of
reverting back to a classical parental form possessing a cell wall (8). Therefore, stable L
form CWDB are genetically different from their parent strain. In contrast, unstable L
forms retain their ability to revert back to the parental form and are considered
genetically identical to the parent strain (9). Also, L forms can be further classified as
spheroplasts or protoplasts. Cells that retain a residual cell wall are defined as
spheroplasts, while those cells completely lacking a cell wall are protoplasts. Finally, L
form bacteria exhibit a classic "fried egg" appearance when grown on solid media but L
form manipulation may also be performed in liquid media.
Currently, renewed interest in L form bacteria has occurred due to their
association with antibiotic resistance and certain disease states. L form bacteria gain
many advantages including resistance to cell wall-targeting antibiotics, resistance to
bacteriophage infection and faster growth in nutrient rich environments at the cost of
losing mobility (lacking fimbrae and flagella) (7-13). In contrast, L form bacteria
develop the disadvantage of osmotic sensitivity and lose genetic transfer ability by
conjugation. In E. coli, the relA, spoT, creC and metB mutations were identified in the
formation of the stable L form strain LW1655F+ (7). Further research showed that
mutations also existed in critical cell division genes in the dcw cluster in stable L form
bacteria. Therefore, L form bacteria represent a unique convertible phenotype that may
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offer the bacteria various advantages to adapt to a changing environment, including
oxidative stress and DNA damage. Staphylococcus aureus was shown to form unstable L
forms and developed beta-lactam resistance in revertants (8). Genetic analysis of E. coli
unstable L forms undergoing cell division identified regulatory and structural colanic acid
mutants and an mrcB penicillin-binding protein (PBP) 1B mutant defective in L form
development (9). Furthermore, preliminary whole genome transcriptome analysis of E.
coli mutants defective in L form development showed these mutations were also critical
in DNA repair, oxidative stress response and acid tolerance pathways (13).
Since the discovery of cell penetrating peptides in 1988, new attributes and
functions have been identified demonstrating broad therapeutic applications.
Structurally, cell penetrating peptides (CPPs) are composed of relatively short basic
sequences of 5 to 40 amino acids and possess the ability to cross the cell membrane
through a number of mechanisms. While all CPPs share membrane translocation activity
the entry mechanisms may differ. The CPP membrane translocation process appears to
be dependent on the cell type and the cargo that may be conjugated to the CPP (14).
Recent studies suggest that most CPPs enter eukaryotic cells through endocytosis uptake
mechanisms, however small arginine-rich CPPs have been shown to cross the plasma
membrane in an energy independent process (15). CPPs can utilize both the clathrindependent and clathrin-independent endocytosis pathways to gain entrance into the cell
and are able to escape from the endosomes to the cytoplasm. Translocation from the
endosome appears to be facilitated by endosome acidification allowing the CPP to cross
the lipid bilayer (14, 16, 17). Recently, YopM, a protein associated with Yersinia
enterocolitica infection, was shown to have cell translocation capability. Normally,
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YopM and other pathogenic proteins pass through the cell membrane via the type III
secretion system (T3SS). This activity was attributed to two highly cationic amino acid
regions within two alpha helices in the N-terminus and demonstrated the ability to
translocate a fused protein cargo across the cellular membrane (18).
The transmembrane activity of CPPs and CPP fusion proteins represents new engineering
opportunities with vast therapeutic applications. CPPs have been shown to deliver a
variety of cargo including short inhibiting RNA, plasmids, proteins, liposomes, drugs and
fluorescent markers, and represent a powerful strategy for drug delivery. This strategy
can be used to increase cancer cell activity of these anticancer agents by facilitating their
delivery into tumor cells. Furthermore, the CPP transmembrane activity showed that drug
resistant cancer cells could be reverted back to a drug sensitive phenotype by conjugating
CPP with Taxol and other known anticancer drugs by increasing intracellular drug
concentrations (19). Also, CPPs conjugated with protein or protein domains can be used
to specifically target pathways associated with a pro-cancer cell state or apoptosis
pathways leading to cell death of cancer cells. While cell targeting for most CPPs is
ambiguous, recent studies identified CPPs with tumor targeting capabilities (20). Finally,
fluorescent labeled-CPP conjugates have been developed for surgical cancer therapy.
The fluorescent-CPP with an antibody specific for the cancer cells facilitates the
endosomal escape of the conjugate preserving the fluorescent signal within the cancer
cell cytoplasm for easy surgical removal of only tumor tissue (21). Therefore, these
unique peptides offer a variety of engineering options for the development of new
anticancer agents and many other therapeutic applications.
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However, many challenges remain to efficiently express and purify functional
CPPs and recombinant proteins in E. coli systems. While CPPs can be chemically
synthesized and purified from inclusion bodies, but both strategies have drawbacks
related to proper protein folding and function. Also, the chemical synthesis strategy
continues to cost more than traditional E. coli expression and purification systems
expanding costs to downstream applications. In contrast, protein secretion to the media
has the advantage of preserving protein structure; however secretion pathways are limited
due to the cell wall barrier. Secretion of CPP fusion proteins to the periplasm may allow
the translocation of the CPP fusion protein to the media or production of cell wall
deficient L form strains could be generated to directly secrete CPP fusion proteins into
the media. Here we describe the generation of unstable L form spheroplasts that allowed
secretion to the media and subsequent purification of a CPP fusion protein with broad
anticancer activity.

3.3. Materials and Methods

3.3.1. Bacterial strains, plasmids, culture conditions, and general molecular biological
manipulations.
The bacterial strains and plasmids used in this study are listed in Table 6. Culture
conditions for general molecular biological manipulations were performed as described
(22), or according to standard protocols (23). Primers used to amplify and synthesize the
corresponding DNA sequences are listed in Table 7. The yopM75 sequence was amplified
from genomic Yesinia enterocolitica O8 strain JB580v DNA. Sequential addition of

67

ompF and MDP DNA sequences were constructed using a two-step overlap Phusion
DNA polymerase (New England Biolabs) PCR protocol using 20 nM of each synthesis
primer and target yopM75 sequence for five PCR cycles. After five cycles, each
amplification primer was added to a final concentration of 0.5 M to the reaction mixture
to synthesize the full length product. The PCR products and pET29a plasmid were
digested with NdeI and XhoI and ligated to produce the final vector constructs with the
ompF signal sequence and MDP sequence added to yopM75 in pET29a vector (Table 6).
The sequences of the modular expression cassette are listed in Table 8.

3.3.2. Protein purification and protein identification by Western blot analysis.
Wild-type E. coli BL21 (DE3) and E. coli BL21 (DE3) containing the pET29ompF-yopM75-MDP construct were grown at 37˚C in LB or Pennassay L form production
media containing 40 g/ml of kanamycin and were induced with 0.5 M IPTG (isopropyl
β-D-1-thiogalactopyranoside, Sigma Aldrich) during mid-log phase. Protein samples of
whole cell, cell pellet, cell cytoplasm supernatant, periplasmic proteins and media
secreted protein fraction were prepared according to standard protocols (23). Protein
samples were fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and analyzed by Western blotting. Polyclonal immunoglobulin antibody
against 6X His tag prepared from mouse was used as the probe and was incubated with E.
coli BL21 (DE3) control and the expressed protein samples. BCIP/NitroBT (Sigma
Aldrich) substrate was used to detect an anti-mouse secondary antibody conjugated with
alkaline phosphatase.
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3.3.3. Development of L form bacteria protein secretion system and protein quantification
E. coli BL21 (DE3)/pET29-ompF-yopM75-MDP and E. coli BL21 (DE3)/pET29
constructs were grown at 37˚C in Pennassay media containing 40 µg/ml of kanamycin.
Mid-log phase cultures were incubated with 50 L of 5 mg/mL lysozyme for 2 hours.
Cultures were then induced with 0.5 M IPTG and incubated at 37˚C for 6 to 8 hours. E.
coli BL21 (DE3) constructs were maintained on Pennassay 1.5% agarose media
containing 40 µg/ml and 25 µg/ml ampicillin. Media fractions were separated by
ammonium sulfate precipitation. The 0-40% ammonium sulfate (AS) fraction was
discarded and the 40-70% AS fraction was resuspended in 500 mL of 20 M phosphate
buffer, pH 6.8, and desalted with a ZEBA spin column (Pierce). Desalted samples were
resuspended in 50 mL of 20 M phosphate buffer, pH 6.8 and filtered with a 0.2 micron
filter (Millipore). Manual sample protein purification was performed using a Mono S
5/50 GL cation exchange column (GE Healthcare) on an ÄKTA FPLC (GE Healthcare)
with 20 M phosphate buffer pH 6.8 system. Samples were washed with buffer A, 20
M phosphate buffer pH 6.8 and eluted by increasing NaCl gradient of buffer B, 20 M
phosphate buffer pH 6.8 with 1 M NaCl. Elution sample concentrations were determined
using Bradford’s reagent (Sigma Aldrich) and comparison to a bovine serum albumin
(BSA) (Sigma Aldrich) standard curve. The elution samples were then pooled together
and the concentration was determined using the Bradford reagent method and lyophilized
(Labconco). 10 mg stocks were preserved in 50% glycerol and stored at -20˚C.

3.3.4 Cancer cell cultures, MTT viability and apoptosis assays

69

Cytotoxicity of O75M to DU-145, H232A and MDA-MB-231 cells was studied
using the MTT assay. First, cells (5 × 104) were incubated for 24 h in RPMI 1640
supplemented with 10% FBS and 2 mM L-glutamine. A serial dilution (100 M to 1
nM) from the media purified O75M 10 mg stock was generated was generated with a
final glycerol concentration of 0.5%. Thereafter, the cells were washed and plated with
O75M samples in triplicate in 96-well plates and cultured for 48 h. The cells were then
incubated for 4 h with RPMI 1640 containing 250 µg/mL of MTT. After discarding the
culture medium, 200 µL of DMSO was added to dissolve the precipitates, and the
resulting solution was measured for absorbance at 570 nm with a reference wavelength of
690 nm using an Infinite200Pro plate reader (Tecan). Significant differences between
samples in cytotoxicity between treatment groups were determined using a two-tailed
Student's t-test with p < 0.05 being considered significant. Apoptosis analysis was
performed with ApoTox-Glo Triplex Assay kit (Promega) and results analyzed for
fluorescence and luminescence with the Infinite200Pro plate reader (Tecan).

3.4. Results and Discussion

3.4.1. Cell penetrating peptide synthesis and secretion model design.
Development of a functional E. coli CPP expression system allows rapid CPPfusion protein production for a broad CPP based anticancer agent production program.
The CPP expression system was designed to utilize both ligation and DNA synthesis
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approaches to develop functional CPP and CPP fusion protein products. Previous
identification of transmembrane activity in the N-terminal α-helices of YopM, a T3SS
protein associated with Salmonella enterocolitica infection, provided a CPP from a
bacterium that was capable of expression in E. coli BL21(DE3), albeit in inclusion
bodies (18). Primers designed to amplify the first 73 amino acids of yopM, associated
with the two N-terminal α-helices with two extra C-terminal amino acids used as a linker
for addition of a protein cargo allow the CPP to be cloned into pET29a. Addition of
ompF signal sequence to export the CPP/CPP cargo peptide via cellular secretion
pathways was designed to use a primer overlap PCR strategy with the 5' end of the yopM
sequence. Also, a DNA synthetic approach was used to add the mitochondrial disrupting
peptide (MDP) sequence through overlapping primers complementing the 3' end of the
yopM75 sequence. The MDP sequence was previously reported to have cancer
cytotoxicity inducing apoptosis (24). The final ompF-yopM75-MDP construct will be
cloned into pET-29a to produce the expression vector pET-29-ompF-yopM75-MDP (Fig.
12A; Fig. 12B). Utilizing the NdeI and XhoI restriction enzymes allows expression of the
CPP fusion protein with a C-terminal 6x His-tag. The addition of the 6x His-tag CPP can
be used both in purification and identification of the CPP-fusion protein by Ni-NTA
column and Western blot, respectively.

The addition of the ompF signal sequence

directs the nascent CPP to the Type I secretion pathway for export into the periplasm and
ultimately into the media for purification (25). Export of CPP proteins into the periplasm
allows bi-direction transmembrane activity of the CPP to partially or completely escape
into the media for purification. Furthermore, this model accounts for alternate methods
for the release of the CPP construct into the media. Possible strategies for the cellular
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CPP release include the addition of cell wall permeabilization agents like glycerol or
formation of L-form E. coli BL21(DE3) spheroplast or protoplast expression strains to
facilitate or increase CPP secretion into the media (26).

Figure 12. Model of CPP secretion system. (A) Expression cassette modular design
with an inducible promoter, ompF signal sequence, CPP (yopM75) and MDP
(mitochondrial disrupting peptide). (B) Plasmid pET29-ompF-yopM75-MDP construct
with kanamycin resistance. (C) OmpF signal sequence directed Type I secretion pathway
export of CPP to periplasm and release into the media. (D) Increased CPP export into the
media can be achieved by agents that increase outer membrane permeability or degrade
the cell wall. (IM, inner membrane; PG, peptidoglycan; OM, outer membrane)

3.4.2. Identification, cloning and expression of potential cell penetrating peptides.
Construction of a CPP with anticancer activity was based on the model design.
First, yopM75 was amplified by PCR, digested with NdeI/XhoI and ligated into the NdeI
and XhoI sites of pET-29a. The pET-29a-yopM75 construct was used to transform E. coli
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DH5α and were verified by sequencing. Next, the ompF signal sequence and
mitochondrial disrupting peptide sequence (MDP) were added using an overlap primer
extension PCR method to synthesize the ompF-yopM75-MDP construct was digested with
NdeI/XhoI and ligated into NdeI/XhoI sites of pET29a (Table 7). Sequence verified
pET29a- ompF-yopM75-MDP constructs were used to transform the expression strain, E.
coli BL21 (DE3). Protein expression experiments with E. coli BL21 (DE3)/pET29aompF-yopM75-MDP and control strain E. coli BL21 (DE3)/pET29a were performed in 50
mL cultures and induced with IPTG during mid-logarithmic growth. Whole cell fractions
containing the media, cytoplasm and membrane fractions were analyzed by SDS-PAGE
gels to determine protein expression. The whole cell fraction showed the presence of a
13 kDa band visible in the IPTG induced sample (Fig. 13). After cell lysis, a similar
band was found in the cell pellet fraction consisting of insoluble membrane protein and
protein inclusion bodies showing the CPP-fusion protein was expressed but packaged
into inclusion bodies (Fig. 13). This result also showed the OmpF-YopM75-MDP protein
was expressed, but the signal sequence was not cleaved in the whole cell or the cell pellet
inclusion body fraction accounting for the increase in molecular weight. Next, the
periplasmic fraction was examined for protein secretion and in contrast to the cell pellet
fraction, the periplasmic fraction showed an 11 kDa band related to the YopM75-MDP
protein secreted into the periplasm (Fig. 13). This result demonstrated the functional
activity of the OmpF signal sequence directing protein secretion to the periplasm and the
cleavage of the signal sequence upon entering the periplasm. However, examination of
the media for the presence of the YopM75-MDP did not show the release of the protein
through the outer membrane into the media. Previous studies demonstrated the
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localization and accumulation of OmpF signal proteins in the periplasm and counter
reports of extracellular secretion. (25) This result supports the notion that the formation
of inclusion bodies was due to the accumulation of protein in the periplasm and did not
release the protein into the extracellular media due to periplasm crowding. However,
protein expression from a strong promoter like the T7 promoter may offset the balance
between secretion protein synthesis and secretion pathway periplasm export. Also, the
increase inclusion body formation may be a cellular reaction to the cytoplasmic
accumulation of OmpF-YopM75-MDP with inherent toxic properties or induced toxicity
from accumulation.

Figure 13. YopM75-MDP expression and secretion to the media. The initial expression
analysis of the whole cell (WC) fraction showed YopM75-MDP at 13 kDa. Further
analysis showed YopM75-MDP formed inclusion bodies isolated in the cell pellet (Pt)
also at 13 kDa correlating with the YopM75-MDP still possessing the OmpF, signal
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sequence. In contrast, soluble YopM75-MDP was not detected in the cytoplasm
supernatant (Sn) fraction. Examination of the periplasm showed secretion and
accumulation of YopM75-MDP at 11 kDa, related to the excision of OmpF during
secretion. Initial YopM75-MDP was not detected from the media, however when cells
were treated with lysozyme the 11 kDa band was present and corresponded to the release
of YopM75-MDP into the media.

3.4.3. Development of L form E. coli, secretion of peptides to the media and purification.
The secretion of proteins into the media has been extensively researched and often
requires the addition of membrane permeabilization molecules or cell wall disruption
agents. Previous protein export attempts report using molecules like glycerol increase the
diffusion rate of proteins through the cell wall, but the diffusion rates to the growth media
remained slow (26). Therefore, cell wall disrupting agents like penicillin or lysozyme
appear to be the best suited agents for high yield protein secretion systems. The addition
of these agents leads to the degradation of the peptidoglycan layer and either partial or
complete removal of the outer membrane in the production of L-form bacterial
spheroplasts or protoplasts, respectively. In order to construct active protein expression
L-form E. coli BL21(DE3)/ pET29a-ompF-yopM75-MDP cells, 50 mL Penassay broth
media cultures were grown to mid-logarithmic growth and 50 µL of 5 mg/mL lysozyme
stock was added and incubated for 2 hours prior to induction with final IPTG
concentration of 0.5µM. Lysozyme treated and non-treated cultures were streaked on
Pennassay L-form agar media containing kanamycin and ampicillin to compare culture
morphology. Kanamycin was used for selection of strains carrying the pET29 construct,
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while a serial dilution of ampicillin was used to test for L-form phenotype demonstrating
increased resistance to peptidoglycan targeting antibiotics like ampicillin. The remaining
culture was analyzed for protein secretion into the media.

Figure 14. Formation of L form BL21 (DE3) E. coli. Parental E. coli BL21 (DE3)
colonies demonstrate tan colonies with distinct boundries (A), while lysozyme treated E.
coli BL21 (DE3) formed white/milky mucoid colonies depicting L form phenotype (B).
Morphology analysis by TEM at 17,000X showed parental E. coli BL21 (DE3) cells as
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smooth rod shaped bacteria (C). In contrast, L form E. coli BL21 (DE3) showed a round,
cocoid bacteria with frayed outermembrane and the presence of membrane blebs (D).

Examination of the cell culture morphology showed a difference between lysozyme
treated and non-lysozyme treated cells. Lysozyme treated cell formed large white and
tan mucoid colonies with undefined boundaries, while the untreated cells formed tan oval
colonies with defined boundaries (Fig 14A; Fig. 14B). Next, the cell phenotype was
analyzed by TEM to identify the presence of L-form spheroplasts or protoplasts. TEM
micrographs of lysozyme treated sample showed the presence of round cells, with partial
attachment of the outer membrane and membrane blebbing (Fig. 14D). In comparison,
the untreated cells were rod shaped with a smooth outer membrane (Fig. 14C). These
results, showed the formation of L-form spheroplasts from E. coli BL21 (DE3)/ pET29aompF-yopM75-MDP cells with similar colony morphology and cellular phenotypes to
previously described L form bacteria (13).
Comparison of media fractions between lysozyme treated cultures and non-lysozyme
treated cultures showed the presence of an 11 kDa protein in the lysozyme treated
cultures. This protein correlates with the protein identified in the periplasmic fraction of
similar molecular weight (Fig. 13). This protein was purified by anion exchange
chromatography with a yield of 32 mg/L and produced an elution protein at 11 kDa
correlating to both the periplasmic and media fractions (Fig. 15). This protein was
confirmed by antibody detection of the C-terminal His tag using Western blot analysis,
which verified the presence of YopM75-MDP in the media post lysozyme treatment.
Next, the elution samples were pooled and dialyzed to reduce contaminating salt
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concentrations. The pooled sample was concentrated by lyophilization and resuspended
in 50% glycerol for storage. The purification of YopM75-MDP represents a fast and
efficient strategy for the secretion and purification of CPP fusion proteins by utilizing the
unique cell wall deficiencies of L form E. coli BL21 (DE3) cells. The rapid generation of
CPPs and CPP fusion proteins can be used to produce therapeutic concentration and test
for novel activities.

Figure 15. Purification of YopM75-MDP from the media. The prepared media fractions
were separated and purified by anion exchange chromatography yielding a single band at
11 kDa corresponding to YopM75-MDP (*).

3.4.4. Antiproliferative activity of CPP.
Cancer cell viability screening demonstrated YopM75-MDP antiproliferative
activity toward lung, breast and prostate cancer cell lines. Purified YopM75-MDP was
used for MTT cell viability assays and determined the antiproliferative activity IC50 value
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in the low µM range for each cancer cell type. The IC50 values were calculated to be 2.47
± 0.2µM, 3.27 ± 0.2µM and 6.99 ± 0.12µM for DU-145 prostate cancer cells, H232A
lung cancer cells and MDA MB-231 breast cancer cells, respectively (Fig. 16). The DU145 prostate cancer cell viability assay result was further supported by the Apo-Tox-Glo
result. The IC50 was calculated to be 3.99 ± 0.2µM and was similar to the MTT assay
result. The toxicity assay showed similar fluorescence to the control demonstrating the
cells were not rapidly lysing. While, caspase 3/7 activity increased with increasing
concentrations of YopM75-MDP demonstrating the induction of apoptosis through the
induction of the caspase cascade (Fig. 17). These results show similar cytotoxicity
toward cancer cell lines, while reducing toxicity toward E. coli (24). The MDP sequence
bears high sequence similarity to synthetic antimicrobial peptides that exhibited
cytotoxicity toward E. coli and 3T3 mouse embryonic fibroblasts (27). The addition of a
CPP that originated in Yersinia enterocolitica, a relative of E. coli, would suggest that
antimicrobial activity may be reduced toward bacteria through the fusion of YopM75.
Furthermore, the activity of YopM75-MDP provides further evidence of the vast potential
of CPP fusion proteins. The purification of YopM75-MDP from the media demonstrated
the ability to generate novel E. coli L form expression systems with lysozyme treatment
to release OmpF based signal proteins. Finally, the formation of E. coli L form protein
secretion cells advances our goal toward generating CPP expressing anticancer bio-agents
capable of intra-tumor growth and anticancer protein expression.
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Figure 16. Cancer cell antiproliferation assays. YopM75-MDP was tested for activity
against three cancer cell lines. (A) prostate cancer cell line DU-145, (B) breast cancer cell
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Figure 17. Apoptosis pathway induction assay. YopM75-MDP showed induced caspase
activity in prostate cancer cell line DU-145. Also, YopM75-MDP did not show increased
toxicity, while demonstrating similar cell viability results to the MTT analysis.
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Table 6. Bacterial strains and plasmids used in this study
Source or
a

Strains or plasmids
Yesinia enterocolitica O8

Description

reference

Wild type strain

strain JB580v

Escherichia coli
DH5

General cloning host

Lab stock

BL21(DE3)

Host strain for heterologous gene expression

Novagen

SW01

BL21(DE3) harboring pET29

This work

SW02

BL21(DE3) harboring pET29-ompF-yop75-MDP

This work

Kanr, general cloning vector

Novagen

Plasmids
pET29
pET29-yop75
pET29-ompF-yop75
pET29-ompF-yop75-MDP

r

This study

r

This study

r

This study

Kan , yop75 CCP cloned into MCS
Kan , yop75 with ompF signal sequence
Kan , yop75 with ompF signal sequence and MDP gene
sequence

a

b

r

Kan , kanamycin resistance; MCS, multiple cloning site; MDP, mitochondrial disrupting peptide.
strain was provided as a gift by Dr. Kristen Walker, University North Carolina (UNC) School of Medicine.
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Table 7. Primers used for construction of CPPs and gene expression
Sequence (5’  3’)a

Name (primers sorted by

Gene Name

gene)
FP-yop75-NdeI

CTAGCACATATGTTTATAACTCCAAGAAATGTATC

RP-yop75-BamHI-XhoI

CGCTCGAG GGATCCGGCTTGTCGGTCCAGGC

yop75

Amplification primer
FP-OmpF-SRP OV-NdeI

CTAGCACATATGATGATGAAGCGCAATATTCTG

ompF signal
sequence

Synthesis primers
FP-OmpF-SRP OV2

GCTCTGTTAGTAGCAGGTACTGCAAACGCTTTTAT
AACTCCAAGAAATGTATC

RP-OmpF-SRP OV

TGCAGTACCTGCTACTAACAGAGCAGGGACGATC
ACTGCCAGAATATTGCGCTTCATCAT

Amplification primer
RP-MDP-CPP-XhoI

CCCTCGAGTTTCGCCAGTTTCGCCAG

MDP

Synthesis primer
RP-CPP-MDP-OV

TTTCGCCAGTTTCGCCAGTTTTTTCGCCAGTTTCGC
CAGTTT GGCTTGTCGGTCCAGGC

a

Sequences in capital letters are designed either to provide restriction sites (underlined)

for directional cloning, or to provide extra base(s) in front of restriction sites for efficient
restriction enzyme digestion, or to provide overlapping sequences for CPP expression
cassette assembly during multiplex PCR.
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Table 8. DNA and Protein sequences
Name of Sequence

Sequence (5’  3’)a

ompF signal sequence

ATGATGAAGCGCAATATTCTGGCAGTGATCGTCCCTGCTCTGTTA
GTAGCAGGTACTGCAAACGCT

OmpF signal sequence

MMKRNILAVIVPALLVAGTANA

yopM75

ATGTTTATAACTCCAAGAAATGTATCTAATACTTTTTTGCAAGAAC
CATTACGTCATTCTTCTGATTTAACTGAGATGCCGGTTGAAGCAG
AAAATGTTAAATCTAAGACTGAATATTATAATGCATGGGCGGTAT
GGGAACGAAATGCCCCTCCGGGGAATGGTGAACAGAGGGAAATG
GCGGTTTCAAGGTTACGCGATTGCCTGGACCGACAAGCCGGATCC
TCTAGAGTCGACCTGCAGGCATGCAAGCTTGCGGCCGCACTCGAG
CACCACCACCACCACCACTGAGATCCGGCTGCTAACTCGAC

YopM75

MFITPRNVSNTFLQEPLRHSSDLTEMPVEAENVKSKTEYYNAWAVW
ERNAPPGNGEQREMAVSRLRDCLDRQALE

MDP

AAACTGGCGAAACTGGCGAAAAAACTGGCGAAACTGGCGAAA

MDP

KLAKLAKKLAKLAK

ompF-yopM75-MDP

ATGATGAAGCGCAATATTCTGGCAGTGATCGTCCCTGCTCTGTTA
GTAGCAGGTACTGCAAACGCTATGTTTATAACTCCAAGAAATGTA
TCTAATACTTTTTTGCAAGAACCATTACGTCATTCTTCTGATTTAA
CTGAGATGCCGGTTGAAGCAGAAAATGTTAAATCTAAGACTGAAT
ATTATAATGCATGGGCGGTATGGGAACGAAATGCCCCTCCGGGG
AATGGTGAACAGAGGGAAATGGCGGTTTCAAGGTTACGCGATTG
CCTGGACCGACAAGCCAAACTGGCGAAACTGGCGAAAAAACTGG
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CGAAACTGGCGAAA

OmpF-YopM75-MDP

MMKRNILAVIVPALLVAGTANAMFITPRNVSNTFLQEPLRHSSDLTE
MPVEAENVKSKTEYYNAWAVWERNAPPGNGEQR
EMAVSRLRDCLDRQAKLAKLAKKLAKLAK
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CHAPTER 4

SIGNIFICANCE AND FUTURE DIRECTIONS
Engineering of CPP anticancer bio-agents
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4.1. Significance of Research
The development of new anticancer agents with the ultimate goal of preventing
and curing cancer has been the goal of researchers for many years. Current anticancer
strategies employ a number of agents including natural products or peptide anticancer
agents that target cancerous or pro-cancerous cell states. Cancer drug targets include
many distinct cancer pathways such as metabolic, apoptosis, genetic and epigenetic that
distinguish individual cancer cell lines.
Many epigenetic targets have demonstrated their potential as a cancer therapy and
continuing research in HDAC inhibition is focused on isoform-specific agents like
FK228 that display better pharmacological properties that pan-HDAC inhibitors (1).
Since the approval of FK228 by the FDA for cutaneous T-cell lymphoma more
depsipeptide compounds like the thailandepsins and spiruchostatins have been identified
with different HDAC selectivity and the potential to target different cancer types (2, 3).
These depsipeptides share similar genetic organization and biosynthetic pathways and
offer an opportunity for engineering hybrid depsipeptides with novel HDAC inhibitory
function.
Further research of the FK228 biosynthetic pathway showed the in trans
recruitment of both a Ppant transferase and an AT domain during the production of
FK228. The stand alone AT domain and Ppant transferase in C. violaceum were found to
be constitutive genes suggesting that these proteins may be involved in essential cell
functions. The Sfp-type Ppant transferases found within the gene clusters are often
dispensable for the associated polyketide or NRPS biosynthesis. However, our research
suggests that Sfp-type Ppant transferases are essential to C. violaceum and the true
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physiological role(s) for stand-alone Ppant transferase remains to be established.
Previous research demonstrated and increased physiological role where the broad
spectrum activity of Sfp-type Ppant transferases substituted Ppant transfer activity for
fatty acid biosynthesis in B. subtilis and Pseudomonas aeruginosa in the absence of
ACPS-type Ppant transferases (4, 5).
The "stand alone" AT domain in C. violaceum demonstrated the first evidence of
"cross talk" between modular NRPS-PKS systems and fatty acid biosynthesis pathways.
The bridge between fatty acid biosynthesis and polyketide synthesis has been addressed
previously in Streptomyces species containing many type II polyketide synthases which
are analogous to the type II fatty acid biosynthetic pathway composed of discrete
proteins. Early findings showed S. coelicolor contained three different ACP-like
proteins, rather than a single ACP, that were not shared among PKS and fatty acid
biosynthesis pathways providing one level of pathway specificity (6). Furthermore,
FabD, the malonyl-CoA:AcpP acyl-transferase found in fatty acid biosynthesis was
shown to be active on both AcpP and type II PKS ACPs (7). FabD is often found within
the fatty acid biosynthetic operon (E. coli) and a homologue from the fatty acid
biosynthesis operon in S. glaucescens was shown to transfer malonate to both
tetracenomycin (Tcm) ACP and fatty acid ACP. Alternatively, pathway specificity may
be determined by the carrier domains and the specific docking domain protein-protein
interactions allow for the proper biosynthesis of fatty acid biosynthesis, PKS and NRPS
pathways. Future research on the docking domains of ACPs will address questions
associated with the similarity to fatty acid ACPs to elucidate the specificity and
additional functions of these domains. The expanded physiological roles of Ppant
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transferases and acyl transferases suggests that they may represent new targets for
antimicrobial treatment of bacteria that have these enzymes associated with essential
pathways like fatty acid biosynthesis.
The future of CPP research will continue to develop new applications further
enhancing the broad range of CPP activities. Our research shows the engineering
potential of CPPs for the development of new therapeutic agents. However, in the future
we would expand this project to engineer and express CPPs and CPP-fusion peptides in
E. coli that can target specific cells, differentiate healthy from unhealthy cells and interact
with specific intracellular pathways. This new method for releasing the outer cell wall
through L form bacteria production allowed CPP-MDP secretion to the media for rapid
purification and may be expanded to purify new CPP-fusion constructs to test for
anticancer activity. The secretion of CDP-MDP into the media was critical for future
research goals toward generating an anticancer CPP tumor targeting bio-agent. Future
experiments may require the development of a stable L form bacteria through genetic
mutation(s) to prevent reversion back to the parental phenotype in the construction of
these new CPP based bio-agents. Also, the expression of the CPP may need to be
adapted to the tumor microenvironment depending on the final host selected for growth
and CPP expression within the tumor.

4.2. Targeting the tumor microenvironment
Cancer is a major public health problem facing mankind and yet the development
of effective cancer treatments with no or few side effects remains one of the most
difficult scientific challenges of our time. Cancer occurs in many types (such as breast
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cancer, skin cancer, or leukemia – cancer heterogeneity) and the effectiveness of
conventional treatments (surgical removal, radiotherapy and chemotherapy) varies (8).
Consequently, there have been intensive efforts to develop alternative cancer therapies
including bone marrow transplantation, immunotherapy, gene therapy, hormone therapy,
and inhibition of angiogenesis (formation of blood vessels) or specific protein targets
(mostly kinases) in key signaling pathways, all with mixed success (9). A fundamental
requirement for any cancer therapy is to differentially suppress the proliferation of cancer
cells or selectively eliminate cancer cells, while minimizing toxicity toward normal cells
to an acceptable level.
Most human cancers are solid tumors. Solid tumors generally have an architecture
in which the inner core maintains a very low oxygen microenvironment (known as
“hypoxia”). Hypoxia occurs when tumor mass outgrows angiogenesis 10, 11). The
hypoxic microenvironment of solid tumors often contains areas of necrosis that are
resistant to both radiotherapy and chemotherapy; resistance to chemotherapy is, in part,
due to the poor drug bioavailability as a result of the distance between inner tumor mass
and peripheral blood vessels. Solid tumors with a hypoxic/necrotic core are also
predisposed to increased tumor spreading (known as “metastasis”) (12). Paradoxically,
the pathophysiologic characteristics of hypoxia in solid tumors also provide a unique
opportunity for the development of tumor-selective treatments, including prodrugs
activated by hypoxia, hypoxia-specific gene therapy, targeting the hypoxia-inducible
transcription factor, and also the use of anaerobic bacteria as tumorcidal bio-agents (12).
The early observations of cancer regression following bacterial infections in patients has
inspired active pursuits of nonpathogenic anaerobic bacteria as anticancer bio-agents over
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the last 60 years (13-15). In fact, the human body between external skin and inner
digestive lumen is normally well oxygenated except for the hypoxic/necrotic cores within
solid tumors where some anaerobic bacteria administered systemically through the blood
circulation, or injected locally into solid tumors, can infiltrate and proliferate. As a
consequence, tumor mass in the bacteria-colonized regions is selectively destroyed
(known as “oncolysis”) and nutrients released are consumed by the bacterial population.
The first generation of anticancer bio-agents were natural isolates of facultative or
obligate anaerobic bacteria, belonging to the genus of Bifidobacterium, Clostridium, or
Salmonella. Experiments performed on animal models or cancer patients demonstrated
that administered bacterial spores or vegetative cells germinate and/or multiply in the
hypoxic/necrotic regions of solid tumors, and that therefore limited oncolysis in these
tumor regions can occur. However, a common problem hindering this approach is that
anaerobic bacteria die when they reach to the outer layers of solid tumors where oxygen
levels elevate. Some bacterial strains also produced endotoxins that resulted in excessive
cytotoxicity toward normal cells, which inspired the creation of attenuated strains with
proven safety records (16-18). Thus, the first generation of anticancer bio-agents could
only destroy the inner parts of solid tumors but could not completely eradicate them;
tumors would re-grow from the remaining viable outer rings.
The second generation of anticancer bio-agents were genetically engineered anaerobic
bacteria that produce prodrug-activating enzymes or tumor necrosis factors (13, 19).
Prodrugs are injected intravenously and are activated by the enzymes at the sites of
bacterial spore germination and vegetative growth inside solid tumors. This generation of
anticancer bio-agents achieved greater oncolytic effects and some of them have actually
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entered clinical trials, but the results have still not been sufficient to warrant practical
cancer therapy. The effectiveness of prodrug injections is hampered by poor prodrug
bioavailability due to the distance between peripheral blood vessels and the hypoxic core;
an extra dose of tumor necrosis factor only slightly enhanced the necrosis in the already
necrotic regions of solid tumors. Further improvement by combining anticancer bioagents with vascular-targeting chemicals resulted in still only modest increases of
oncolytic activity (19). Nevertheless, the benefits of exploiting tumor hypoxia for cancer
therapy have yet to be fully realized (12).

4.3. Selection of anaerobic expression host
The production and secretion of CPPs will generate a new anticancer treatment
combining the tumor targeting and anticancer activities of the bacteria with the anticancer
activity of the CPPs. The continuing anticancer CPPs development in E. coli
BL21(DE3) can lead to the engineering of many specific anticancer agents that are
capable of targeting multiple pathways to treat cancer. E. coli BL21(DE3) can be used to
engineer the anaerobic expression cassette, the integration of the expression into bacterial
chromosome and CPP secretion into the media. E. coli BL21(DE3) has been used
successfully to express and secrete the CPP fusion proteins into the media. A secondary
benefit of engineering E. coli strains is the potential for large scale media production of
CPPs, because most current CPPs are chemically synthesized or derived from peptide
digestion. The expression cassettes constructed in E. coli strains can be easily modified
by exchanging promoters and signal sequences targeting protein secretion pathways that
work in different recipient anaerobic bacterial hosts such as Bifidobacterium longum and
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attenuated Salmonella typhimurium. Both B. longum and S. typhimurium have higher
(G+C) contents than that (50.8%) of E. coli, therefore codon usage would be evaluated
and adjusted to accommodate these differences. Although B. longum and attenuated S.
typhimurium have some shortcomings (Table 10), currently they are the best practical
hosts for this research. Clostridium novyi-NT and Clostridium sporogenes are Grampositive, spore-forming, strictly obligate anaerobic bacteria and have demonstrated strong
oncolytic effects with a high degree of safety. Although they would be adaptable hosts
for the purpose, they are recalcitrant to genetic manipulation making them more difficult
to use for this research (20). Transfer of the anaerobic expression cassette and integration
into the genome of Clostridia strains represents a formidable task and may require new
methods for efficient genetic transformation. Also, since CPPs have shown greater
antibacterial activity toward some Gram-positive bacteria than Gram-negative, both
Clostridiaand Bifidobacterium may present additional challenges to CPP secretion
system engineering (21,22). Therefore, strains of Clostridia and Bifidobacterium are
considered as secondary candidates for this research.
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Table 10.. Parts of data were adopted from (13-15); E. coli strains are chosen as priming hosts for pilot experiments.
Genus/Species

a

b

Available?

c

Genetically Engineerable?
(Comment/Reference)
Yes (Genetic workhorse) (21)

(G+C)
d
Content
50.8

E. coli BL21(DE3)
or variant strains

Commercial
sources

B. adolescentis
B. bifidum
B. infantis
B. longum

Private,
Public
-

Yes (22)
Unknown (22)
Yes (22)
Yes (23,24)
Yes (25)

30.9

Private

No (16,20)

28.9

Private,
Public

Unknown (16)
Yes but very difficult (26, 27)

Private,
Public

Yes (28)
Yes (29, 30)

C. acetobutyricum
(C. beijerinckii)
C. novyi-NT and
derived strains
(attenuated)
C. sordellii
C. sporogenes
(C. butyricum)
(C. oncolyticum)
S. choleraesuis
S. typhimurium
VNP20009
(attenuated)

59.2
~59-61
60.1

~28-30
~28-30

52.1
52.2

Advantages

e

Disadvantages

e

- Easy genetics
- Collateral benefit
- Good for pilot experiments
- Non-toxic
- Intravenous or oral
administration
- Modestly high (G+C)%
content

- Alone not strong oncolytic
- Non-spore former

- Spore former
- Spores are easy to produce,
stable and economical to use
- Intravenous administration
- Demonstrated strong
oncolytic ability
- Demonstrated safety of
nonpathogenic strains
- Attenuated strains available

- Some strains are pathogenic
- Strain variation exists
- Very low (G+C)% content
- Difficult genetics

- Intrinsic antitumor activity
- Can target both large and
small tumors
- Attenuated strains available

- Wild-type strains are
pathogenic
- Safety is a concern
- May induce weak innate
immune response
- Alone not strong oncolytic

- Alone not strong oncolytic
- Non-spore former
- Difficult to store and handle
- Susceptible to non-permissive
conditions

Priority

f

Pilot/1st

1st

2nd

2nd

1st

E. coli, Escherichia coli – Gram-negative, facultative, suitable for pilot experiments; B, Bifidobacterium – Gram-positive, obligate anaerobe; C, Clostridium - Gram-positive, strictly obligate anaerobe;
S, Salmonella - Gram-negative, facultative anaerobe. Several strains of C. acetobutyricum were renamed as C. beijerinckii. Several strains of C. oncolyticum used to be named C. butyricum, and later
renamed as C. sporogenes.
b
Private, private sources through (intended) collaborations; Public, public sources such as strain stock centers; -, not concerned.
c
Genetic engineerability refers to the availability of appropriate vectors and proven methods of bacterial transformation.
d
The (G+C) contents, wherever available, are from microbial genome databases. ~, Estimated. A close (G+C) content assumes similar codon usages.
e
Advantages/disadvantages collectively refer to the genus.
f
Subject to personal judgment.
a

98

Figure 18.

Anticancer bio-agent experimental design image.

A) Engineering of

anticancer tumor targeting bacterium shows induction of gene expression in an anaerobic
environment leading to secretion of anticancer cell penetrating peptide (CPP) and
production of a reporter protein (Gfp). B) The expression cassette module is activated
under hypoxic condition leading to gene expression of CPP and reporter genes. C)
Production and formulation of bacterial spores or bacteria for testing in mouse cancer
model. D) Future systemic application of tumor targeting CPP expressing anticancer
bio-agents. Part D was adapted with permission from (31).

4.4. CPP fusion peptide expression cassette design
Efficient production of CPPs in engineered bacteria requires all the necessary
genes to be arranged properly under the proper regulatory circuits. Specifically, designing
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the expression cassette with four exchangeable modules will allow rapid amendments to
each individual component of the CPP expression system. The first module will contain
an interchangeable promoter from the given host genome so that the expression of the
CPP gene is controlled by environmental influences simulating a hypoxic tumor
microenvironment (Fig. 18B). Since the genome sequences of all prioritized host
bacteria but C. sporogenes are available, promoters activated under hypoxic growth
conditions can be identified and verified experimentally. The second module will contain
a signal sequence that directs the peptide to the corresponding protein secretion pathway.
The third module will contain the CPP with transmembrane activity that can carry an
anticancer protein or protein domain such as MDP, directed toward apoptosis or cancer
pathways (Fig. 18A). Some additional CPPs that possess inherent domain targeting
ability that have anticancer activity could be used to increase the number of anticancer
peptides expressed by the host (Table 10). The CPPs may be modified to contain a small
peptide or protein fusion product with known function to block protein/protein
interactions and inhibit cell proliferation or induce apoptosis. The fourth module allows
for co-expression of a fusion protein, another CPP, or a fluorescent marker gene (gfp)
from the same promoter. However, the fourth module may be optional. In order to
facilitate expression cassette transfer, integration and mutant selection in a receiving host,
a marker gene (conferring antibiotic resistance) driven by a constitutive promoter would
be placed upstream of the expression cassette. Finally, the integration of the expression
cassette into the host genome will be facilitated by transposon insertion to complete the
construction of the anticancer CPP expressing bio-agent (Fig. 18C, Fig. 18D).
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Table 10. Cell penetrating peptides that display promising anticancer activity.
Bactericidal
CPP

Protein Source

Types of Cancer

Mode of Action
activity

PNC-271

Hdm-2 binding

Breast, colon,

Necrosis and p53

protein

osteosarcoma

binding apoptosis

Unknown

(32)
PNC-281

CytC77-101

Hdm-2 binding

Breast, colon,

Apoptosis via p53

protein

bone, pancreatic

(33)

Cytochrome C

Untested

Apoptosis pathway

Unknown

Gram + > Gram-

via mitochondria
(34)
PEGA-pVEG

Vascular homing

Breast

peptide
CB1a

MAP2

Transportin2

1

cecropins

Gram + > Gram-

(35)
Stomach, lung,

Membrane

leaukemia

disruption (36)

Artificial model

Breast, leukemia,

Membrane

amphipathic peptide

melanoma

disruption (37)

Galanin and

Breast, leukemia,

Membrane

mastoparan fragments

melanoma

disruption (37)

Poor activity

Gram + > Gram-

Gram + > Gram-

PNC-27 and PNC-28 were synthesized with penetratin CPP attached to carboxyl terminus of Hdm-2

binding protein that binds p53
2

Anti-angiogenesis

Map and Transportin show hemolytic toxicity

4.5. Anti-tumor activity analysis in mouse tumor models
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Formulated anticancer bio-agents will be tested first on mouse models carrying
human tumor xenografts by intravenous (systematic) injection (38-40). Anaerobic
bacteria have demonstrated the ability to circulate safely through bloodstream, infiltrate
and selectively (germinate if spores) grow inside solid tumors in the hypoxic/necrotic
regions. As a pure physiological consequence, tumor mass will be destroyed and the
released nutrients will be consumed by proliferating bacteria. Secondly, the bacterial
growth under hypoxic conditions will activate gene expression from the anaerobic
promoter and the anticancer cell penetrating peptide will be secreted outside of the cell.
There is no need for injection of other anticancer prodrugs as anticancer CPPs are
produced de novo inside solid tumors. Although obligate and facultative anaerobic
bacteria will cease to grow and eventually die as they progress to the outer rings of solid
tumors where the oxygen levels elevate or evoke an immune response, CPPs will
continue to diffuse and selectively kill proliferating cancer cells. Therefore, a strong
synergy between the physical consumption of cancer mass by engineered anaerobic
bacteria and the anticancer activities of CPPs could have the potential to eradicate many
kinds of solid tumors regardless of cancer genotype. Promising test results on mouse
models would warrant future tests on large animal models and cancer patients according
to preclinical and clinical trials.
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